JP4187413B2 - 遺伝子発現の制御 - Google Patents
遺伝子発現の制御 Download PDFInfo
- Publication number
- JP4187413B2 JP4187413B2 JP2000537990A JP2000537990A JP4187413B2 JP 4187413 B2 JP4187413 B2 JP 4187413B2 JP 2000537990 A JP2000537990 A JP 2000537990A JP 2000537990 A JP2000537990 A JP 2000537990A JP 4187413 B2 JP4187413 B2 JP 4187413B2
- Authority
- JP
- Japan
- Prior art keywords
- gene
- plasmid
- sequence
- pvy
- promoter
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 230000014509 gene expression Effects 0.000 title claims abstract description 124
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 374
- 108700005078 Synthetic Genes Proteins 0.000 claims abstract description 60
- 238000000034 method Methods 0.000 claims abstract description 47
- 230000002068 genetic effect Effects 0.000 claims abstract description 19
- 239000012634 fragment Substances 0.000 claims description 126
- 150000007523 nucleic acids Chemical class 0.000 claims description 106
- 108020004707 nucleic acids Proteins 0.000 claims description 105
- 102000039446 nucleic acids Human genes 0.000 claims description 105
- 125000003729 nucleotide group Chemical group 0.000 claims description 97
- 239000002773 nucleotide Substances 0.000 claims description 92
- 230000000692 anti-sense effect Effects 0.000 claims description 35
- 230000006870 function Effects 0.000 claims description 34
- 230000003612 virological effect Effects 0.000 claims description 29
- 230000035897 transcription Effects 0.000 claims description 19
- 238000013518 transcription Methods 0.000 claims description 19
- 102000004169 proteins and genes Human genes 0.000 claims description 12
- 108091026890 Coding region Proteins 0.000 claims description 10
- 108700005077 Viral Genes Proteins 0.000 claims description 7
- 108091081548 Palindromic sequence Proteins 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- 239000003085 diluting agent Substances 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 5
- 101710132601 Capsid protein Proteins 0.000 claims description 3
- 101710094648 Coat protein Proteins 0.000 claims description 3
- 102100021181 Golgi phosphoprotein 3 Human genes 0.000 claims description 3
- 101710125418 Major capsid protein Proteins 0.000 claims description 3
- 101710141454 Nucleoprotein Proteins 0.000 claims description 3
- 101710083689 Probable capsid protein Proteins 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 108010026228 mRNA guanylyltransferase Proteins 0.000 claims description 2
- 238000004113 cell culture Methods 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 210000000056 organ Anatomy 0.000 abstract description 59
- 230000009261 transgenic effect Effects 0.000 abstract description 26
- 241001465754 Metazoa Species 0.000 abstract description 20
- 238000005516 engineering process Methods 0.000 abstract description 7
- 108020004511 Recombinant DNA Proteins 0.000 abstract description 5
- 230000000754 repressing effect Effects 0.000 abstract description 3
- 239000013612 plasmid Substances 0.000 description 376
- 210000004027 cell Anatomy 0.000 description 134
- 241000709691 Enterovirus E Species 0.000 description 122
- 101150102398 Galt gene Proteins 0.000 description 83
- 210000001519 tissue Anatomy 0.000 description 69
- 241000196324 Embryophyta Species 0.000 description 63
- 241000191478 Lettuce necrotic yellows cytorhabdovirus Species 0.000 description 55
- 101000613620 Homo sapiens Protein mono-ADP-ribosyltransferase PARP15 Proteins 0.000 description 46
- 102100040846 Protein mono-ADP-ribosyltransferase PARP15 Human genes 0.000 description 46
- 239000005090 green fluorescent protein Substances 0.000 description 44
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 43
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 43
- 238000010367 cloning Methods 0.000 description 40
- 108020004999 messenger RNA Proteins 0.000 description 33
- 101100379225 Drosophila melanogaster cass gene Proteins 0.000 description 32
- 241000700605 Viruses Species 0.000 description 31
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 31
- 108700026244 Open Reading Frames Proteins 0.000 description 26
- 210000004102 animal cell Anatomy 0.000 description 25
- 238000003780 insertion Methods 0.000 description 23
- 230000037431 insertion Effects 0.000 description 23
- 108091028043 Nucleic acid sequence Proteins 0.000 description 22
- 108090000765 processed proteins & peptides Proteins 0.000 description 21
- 230000010076 replication Effects 0.000 description 20
- 108020004414 DNA Proteins 0.000 description 18
- 102000004196 processed proteins & peptides Human genes 0.000 description 17
- 230000001105 regulatory effect Effects 0.000 description 17
- 108010066133 D-octopine dehydrogenase Proteins 0.000 description 16
- 210000003527 eukaryotic cell Anatomy 0.000 description 16
- 238000013519 translation Methods 0.000 description 16
- 239000002299 complementary DNA Substances 0.000 description 15
- 229920001184 polypeptide Polymers 0.000 description 15
- 238000013459 approach Methods 0.000 description 14
- 239000003550 marker Substances 0.000 description 13
- 239000013598 vector Substances 0.000 description 13
- 230000000295 complement effect Effects 0.000 description 12
- 230000014621 translational initiation Effects 0.000 description 11
- 230000004927 fusion Effects 0.000 description 10
- 230000008488 polyadenylation Effects 0.000 description 10
- 244000052613 viral pathogen Species 0.000 description 10
- 230000036039 immunity Effects 0.000 description 9
- 244000052769 pathogen Species 0.000 description 9
- 230000009467 reduction Effects 0.000 description 9
- 230000002829 reductive effect Effects 0.000 description 9
- 208000024891 symptom Diseases 0.000 description 9
- 230000009466 transformation Effects 0.000 description 9
- 108091081024 Start codon Proteins 0.000 description 8
- 230000001580 bacterial effect Effects 0.000 description 8
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 8
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 8
- 229930027917 kanamycin Natural products 0.000 description 8
- 229960000318 kanamycin Drugs 0.000 description 8
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 8
- 229930182823 kanamycin A Natural products 0.000 description 8
- 239000002245 particle Substances 0.000 description 8
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 8
- 241000894006 Bacteria Species 0.000 description 7
- 125000003275 alpha amino acid group Chemical group 0.000 description 7
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 7
- 239000002953 phosphate buffered saline Substances 0.000 description 7
- 230000008685 targeting Effects 0.000 description 7
- 238000011144 upstream manufacturing Methods 0.000 description 7
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 6
- 241000238557 Decapoda Species 0.000 description 6
- 108700007698 Genetic Terminator Regions Proteins 0.000 description 6
- 101100288095 Klebsiella pneumoniae neo gene Proteins 0.000 description 6
- 229960000723 ampicillin Drugs 0.000 description 6
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 6
- 230000002779 inactivation Effects 0.000 description 6
- 230000007246 mechanism Effects 0.000 description 6
- 239000011859 microparticle Substances 0.000 description 6
- 208000014451 palmoplantar keratoderma and congenital alopecia 2 Diseases 0.000 description 6
- -1 polymerase Proteins 0.000 description 6
- 210000001236 prokaryotic cell Anatomy 0.000 description 6
- 230000002103 transcriptional effect Effects 0.000 description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
- 108020004635 Complementary DNA Proteins 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 241000588724 Escherichia coli Species 0.000 description 5
- 239000012981 Hank's balanced salt solution Substances 0.000 description 5
- 229930193140 Neomycin Natural products 0.000 description 5
- 108091034117 Oligonucleotide Proteins 0.000 description 5
- 102000015636 Oligopeptides Human genes 0.000 description 5
- 108010038807 Oligopeptides Proteins 0.000 description 5
- 108091005804 Peptidases Proteins 0.000 description 5
- 108091034057 RNA (poly(A)) Proteins 0.000 description 5
- 230000003321 amplification Effects 0.000 description 5
- 230000001413 cellular effect Effects 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 229960004927 neomycin Drugs 0.000 description 5
- 238000003199 nucleic acid amplification method Methods 0.000 description 5
- 108091008146 restriction endonucleases Proteins 0.000 description 5
- 238000010561 standard procedure Methods 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 239000013603 viral vector Substances 0.000 description 5
- 229930024421 Adenine Natural products 0.000 description 4
- 241000589155 Agrobacterium tumefaciens Species 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 241000238631 Hexapoda Species 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- 108060004795 Methyltransferase Proteins 0.000 description 4
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 4
- 108091081062 Repeated sequence (DNA) Proteins 0.000 description 4
- 229960000643 adenine Drugs 0.000 description 4
- GFFGJBXGBJISGV-UHFFFAOYSA-N adenyl group Chemical group N1=CN=C2N=CNC2=C1N GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 229940104302 cytosine Drugs 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000010353 genetic engineering Methods 0.000 description 4
- 101150066555 lacZ gene Proteins 0.000 description 4
- 230000001717 pathogenic effect Effects 0.000 description 4
- 230000002441 reversible effect Effects 0.000 description 4
- 229940113082 thymine Drugs 0.000 description 4
- 230000005030 transcription termination Effects 0.000 description 4
- 241000589158 Agrobacterium Species 0.000 description 3
- 108020005544 Antisense RNA Proteins 0.000 description 3
- 241000271566 Aves Species 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 3
- 241000701489 Cauliflower mosaic virus Species 0.000 description 3
- 108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 description 3
- 102000053602 DNA Human genes 0.000 description 3
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 3
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 3
- 102100038132 Endogenous retrovirus group K member 6 Pro protein Human genes 0.000 description 3
- 241000206602 Eukaryota Species 0.000 description 3
- 241000233866 Fungi Species 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 241000208125 Nicotiana Species 0.000 description 3
- 108020004412 RNA 3' Polyadenylation Signals Proteins 0.000 description 3
- 108020005038 Terminator Codon Proteins 0.000 description 3
- 108700009124 Transcription Initiation Site Proteins 0.000 description 3
- 108091023040 Transcription factor Proteins 0.000 description 3
- 102000040945 Transcription factor Human genes 0.000 description 3
- 108060008724 Tyrosinase Proteins 0.000 description 3
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 230000002759 chromosomal effect Effects 0.000 description 3
- 230000004186 co-expression Effects 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 230000001747 exhibiting effect Effects 0.000 description 3
- 230000030279 gene silencing Effects 0.000 description 3
- 238000010363 gene targeting Methods 0.000 description 3
- 238000010348 incorporation Methods 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 239000002054 inoculum Substances 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 230000037426 transcriptional repression Effects 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 241001515965 unidentified phage Species 0.000 description 3
- 241000251468 Actinopterygii Species 0.000 description 2
- 101001004851 Cicer arietinum Legumin Proteins 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- 241000238424 Crustacea Species 0.000 description 2
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 2
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 2
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 2
- 241000701832 Enterobacteria phage T3 Species 0.000 description 2
- 108700023863 Gene Components Proteins 0.000 description 2
- 108010060309 Glucuronidase Proteins 0.000 description 2
- 102000053187 Glucuronidase Human genes 0.000 description 2
- 101001128156 Homo sapiens Nanos homolog 3 Proteins 0.000 description 2
- 101001124309 Homo sapiens Nitric oxide synthase, endothelial Proteins 0.000 description 2
- 108091092195 Intron Proteins 0.000 description 2
- 108060001084 Luciferase Proteins 0.000 description 2
- 241000237852 Mollusca Species 0.000 description 2
- 102100031893 Nanos homolog 3 Human genes 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 108091081021 Sense strand Proteins 0.000 description 2
- 241000700584 Simplexvirus Species 0.000 description 2
- 108091027544 Subgenomic mRNA Proteins 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 108010084455 Zeocin Proteins 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000002238 attenuated effect Effects 0.000 description 2
- 239000013602 bacteriophage vector Substances 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000010307 cell transformation Effects 0.000 description 2
- 230000019522 cellular metabolic process Effects 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 241001493065 dsRNA viruses Species 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- 239000010931 gold Substances 0.000 description 2
- 229910052737 gold Inorganic materials 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- CWCMIVBLVUHDHK-ZSNHEYEWSA-N phleomycin D1 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC[C@@H](N=1)C=1SC=C(N=1)C(=O)NCCCCNC(N)=N)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C CWCMIVBLVUHDHK-ZSNHEYEWSA-N 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 230000001124 posttranscriptional effect Effects 0.000 description 2
- 230000000644 propagated effect Effects 0.000 description 2
- 235000019419 proteases Nutrition 0.000 description 2
- 210000001938 protoplast Anatomy 0.000 description 2
- 230000003252 repetitive effect Effects 0.000 description 2
- 230000003362 replicative effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 235000015170 shellfish Nutrition 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 241001529453 unidentified herpesvirus Species 0.000 description 2
- 230000006648 viral gene expression Effects 0.000 description 2
- 230000029812 viral genome replication Effects 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- RLMLFADXHJLPSQ-NPPFTVEMSA-N (3s,6s,9s,12s,15s,18s,21s,24r,27s)-3,6-dibenzyl-12,24-bis[(2r)-butan-2-yl]-15-(2-hydroxypropan-2-yl)-4,10,16,22-tetramethyl-18-(2-methylpropyl)-9,21-di(propan-2-yl)-13-oxa-1,4,7,10,16,19,22,25-octazabicyclo[25.3.0]triacontane-2,5,8,11,14,17,20,23,26-nonon Chemical compound C([C@H]1C(=O)N2CCC[C@H]2C(=O)N[C@@H](C(N(C)[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N(C)[C@H](C(=O)O[C@H](C(=O)N(C)[C@@H](C(C)C)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N1C)[C@H](C)CC)C(C)(C)O)=O)[C@H](C)CC)C1=CC=CC=C1 RLMLFADXHJLPSQ-NPPFTVEMSA-N 0.000 description 1
- CUJMXIQZWPZMNQ-XYYGWQPLSA-N 13,14-dihydro-15-oxo-prostaglandin E2 Chemical compound CCCCCC(=O)CC[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O CUJMXIQZWPZMNQ-XYYGWQPLSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 241000710929 Alphavirus Species 0.000 description 1
- 241000701513 Badnavirus Species 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 102100026189 Beta-galactosidase Human genes 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- 241000724268 Bromovirus Species 0.000 description 1
- 241000337692 Bunia Species 0.000 description 1
- 235000013049 Bunias Nutrition 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 241000282461 Canis lupus Species 0.000 description 1
- 108090000565 Capsid Proteins Proteins 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- 241000207199 Citrus Species 0.000 description 1
- 241000710151 Closterovirus Species 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 241000938605 Crocodylia Species 0.000 description 1
- 241000724253 Cucumovirus Species 0.000 description 1
- 241000186171 Cyanocorax yncas Species 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 208000035240 Disease Resistance Diseases 0.000 description 1
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
- 241000702463 Geminiviridae Species 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 108020005350 Initiator Codon Proteins 0.000 description 1
- 108010025815 Kanamycin Kinase Proteins 0.000 description 1
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 241000709757 Luteovirus Species 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108700005084 Multigene Family Proteins 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 108091061960 Naked DNA Proteins 0.000 description 1
- 244000061176 Nicotiana tabacum Species 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 241000712894 Orthotospovirus Species 0.000 description 1
- 206010034133 Pathogen resistance Diseases 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 241000286209 Phasianidae Species 0.000 description 1
- IAJOBQBIJHVGMQ-UHFFFAOYSA-N Phosphinothricin Natural products CP(O)(=O)CCC(N)C(O)=O IAJOBQBIJHVGMQ-UHFFFAOYSA-N 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 108010021757 Polynucleotide 5'-Hydroxyl-Kinase Proteins 0.000 description 1
- 102000008422 Polynucleotide 5'-hydroxyl-kinase Human genes 0.000 description 1
- 108010076039 Polyproteins Proteins 0.000 description 1
- 241000709769 Potato leafroll virus Species 0.000 description 1
- 241000710007 Potexvirus Species 0.000 description 1
- 241000710078 Potyvirus Species 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 102000018120 Recombinases Human genes 0.000 description 1
- 108010091086 Recombinases Proteins 0.000 description 1
- 241000702263 Reovirus sp. Species 0.000 description 1
- 241000208422 Rhododendron Species 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 108010003581 Ribulose-bisphosphate carboxylase Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000242583 Scyphozoa Species 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 241000710119 Sobemovirus Species 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 241000723806 Sugarcane mosaic virus Species 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 108700026226 TATA Box Proteins 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 241000724318 Tenuivirus Species 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 241000030538 Thecla Species 0.000 description 1
- 108091036066 Three prime untranslated region Proteins 0.000 description 1
- 241000723717 Tobravirus Species 0.000 description 1
- 241000710141 Tombusvirus Species 0.000 description 1
- 241000219870 Trifolium subterraneum Species 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 1
- 108091005971 Wild-type GFP Proteins 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000016383 Zea mays subsp huehuetenangensis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 108010055615 Zein Proteins 0.000 description 1
- HMNZFMSWFCAGGW-XPWSMXQVSA-N [3-[hydroxy(2-hydroxyethoxy)phosphoryl]oxy-2-[(e)-octadec-9-enoyl]oxypropyl] (e)-octadec-9-enoate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OCC(COP(O)(=O)OCCO)OC(=O)CCCCCCC\C=C\CCCCCCCC HMNZFMSWFCAGGW-XPWSMXQVSA-N 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000002730 additional effect Effects 0.000 description 1
- 101150067366 adh gene Proteins 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 210000004507 artificial chromosome Anatomy 0.000 description 1
- 108010008887 aureobasidin A Proteins 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 239000013601 cosmid vector Substances 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Natural products O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 1
- IAJOBQBIJHVGMQ-BYPYZUCNSA-N glufosinate-P Chemical compound CP(O)(=O)CC[C@H](N)C(O)=O IAJOBQBIJHVGMQ-BYPYZUCNSA-N 0.000 description 1
- 244000005709 gut microbiome Species 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 101150060172 knt gene Proteins 0.000 description 1
- 101150109249 lacI gene Proteins 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 235000009973 maize Nutrition 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- 210000004779 membrane envelope Anatomy 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 238000007479 molecular analysis Methods 0.000 description 1
- 239000002362 mulch Substances 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 108091027963 non-coding RNA Proteins 0.000 description 1
- 102000042567 non-coding RNA Human genes 0.000 description 1
- 108010058731 nopaline synthase Proteins 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000009894 physiological stress Effects 0.000 description 1
- JOHZPMXAZQZXHR-UHFFFAOYSA-N pipemidic acid Chemical compound N1=C2N(CC)C=C(C(O)=O)C(=O)C2=CN=C1N1CCNCC1 JOHZPMXAZQZXHR-UHFFFAOYSA-N 0.000 description 1
- 230000008635 plant growth Effects 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000014493 regulation of gene expression Effects 0.000 description 1
- 230000008844 regulatory mechanism Effects 0.000 description 1
- 230000001718 repressive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 229960000268 spectinomycin Drugs 0.000 description 1
- UNFWWIHTNXNPBV-WXKVUWSESA-N spectinomycin Chemical compound O([C@@H]1[C@@H](NC)[C@@H](O)[C@H]([C@@H]([C@H]1O1)O)NC)[C@]2(O)[C@H]1O[C@H](C)CC2=O UNFWWIHTNXNPBV-WXKVUWSESA-N 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 230000005026 transcription initiation Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 238000011426 transformation method Methods 0.000 description 1
- 230000010474 transient expression Effects 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/67—General methods for enhancing the expression
- C12N15/69—Increasing the copy number of the vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
- C12N15/8216—Methods for controlling, regulating or enhancing expression of transgenes in plant cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
- C12N15/8216—Methods for controlling, regulating or enhancing expression of transgenes in plant cells
- C12N15/8218—Antisense, co-suppression, viral induced gene silencing [VIGS], post-transcriptional induced gene silencing [PTGS]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
- C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
- C12N15/8261—Phenotypically and genetically modified plants via recombinant DNA technology with agronomic (input) traits, e.g. crop yield
- C12N15/8271—Phenotypically and genetically modified plants via recombinant DNA technology with agronomic (input) traits, e.g. crop yield for stress resistance, e.g. heavy metal resistance
- C12N15/8279—Phenotypically and genetically modified plants via recombinant DNA technology with agronomic (input) traits, e.g. crop yield for stress resistance, e.g. heavy metal resistance for biotic stress resistance, pathogen resistance, disease resistance
- C12N15/8283—Phenotypically and genetically modified plants via recombinant DNA technology with agronomic (input) traits, e.g. crop yield for stress resistance, e.g. heavy metal resistance for biotic stress resistance, pathogen resistance, disease resistance for virus resistance
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1048—Glycosyltransferases (2.4)
- C12N9/1051—Hexosyltransferases (2.4.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1241—Nucleotidyltransferases (2.7.7)
- C12N9/127—RNA-directed RNA polymerase (2.7.7.48), i.e. RNA replicase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/503—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from viruses
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/111—Antisense spanning the whole gene, or a large part of it
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
- C12N2310/531—Stem-loop; Hairpin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/10—Applications; Uses in screening processes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2330/00—Production
- C12N2330/30—Production chemically synthesised
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2330/00—Production
- C12N2330/50—Biochemical production, i.e. in a transformed host cell
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2330/00—Production
- C12N2330/50—Biochemical production, i.e. in a transformed host cell
- C12N2330/51—Specially adapted vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/108—Plasmid DNA episomal vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
- C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/15—Vector systems having a special element relevant for transcription chimeric enhancer/promoter combination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/38—Vector systems having a special element relevant for transcription being a stuffer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/55—Vector systems having a special element relevant for transcription from bacteria
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/60—Vector systems having a special element relevant for transcription from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Cell Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2492 | 1998-03-20 | ||
| AUPP2492A AUPP249298A0 (en) | 1998-03-20 | 1998-03-20 | Synthetic genes and genetic constructs comprising same I |
| AUPP2499A AUPP249998A0 (en) | 1998-03-20 | 1998-03-20 | Gene expression I |
| AU2499 | 1998-03-20 | ||
| PCT/AU1999/000195 WO1999049029A1 (en) | 1998-03-20 | 1999-03-19 | Control of gene expression |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2005223953A Division JP4187737B2 (ja) | 1998-03-20 | 2005-08-02 | 遺伝子発現の制御 |
| JP2007302237A Division JP4460600B2 (ja) | 1998-03-20 | 2007-11-21 | 遺伝子発現の制御 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2002507416A JP2002507416A (ja) | 2002-03-12 |
| JP2002507416A5 JP2002507416A5 (https=) | 2007-05-17 |
| JP4187413B2 true JP4187413B2 (ja) | 2008-11-26 |
Family
ID=25645735
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000537990A Expired - Lifetime JP4187413B2 (ja) | 1998-03-20 | 1999-03-19 | 遺伝子発現の制御 |
| JP2005223953A Expired - Lifetime JP4187737B2 (ja) | 1998-03-20 | 2005-08-02 | 遺伝子発現の制御 |
| JP2007302237A Expired - Lifetime JP4460600B2 (ja) | 1998-03-20 | 2007-11-21 | 遺伝子発現の制御 |
| JP2009161847A Expired - Lifetime JP4981103B2 (ja) | 1998-03-20 | 2009-07-08 | 遺伝子発現の制御 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2005223953A Expired - Lifetime JP4187737B2 (ja) | 1998-03-20 | 2005-08-02 | 遺伝子発現の制御 |
| JP2007302237A Expired - Lifetime JP4460600B2 (ja) | 1998-03-20 | 2007-11-21 | 遺伝子発現の制御 |
| JP2009161847A Expired - Lifetime JP4981103B2 (ja) | 1998-03-20 | 2009-07-08 | 遺伝子発現の制御 |
Country Status (20)
| Country | Link |
|---|---|
| US (6) | US20030074684A1 (https=) |
| EP (5) | EP2302057B1 (https=) |
| JP (4) | JP4187413B2 (https=) |
| KR (3) | KR20010042069A (https=) |
| CN (3) | CN101818145A (https=) |
| AT (2) | ATE526406T1 (https=) |
| AU (6) | AU743316C (https=) |
| BR (1) | BRPI9908967B1 (https=) |
| CA (3) | CA2487328A1 (https=) |
| CZ (1) | CZ295108B6 (https=) |
| DK (1) | DK1624060T3 (https=) |
| ES (2) | ES2374290T3 (https=) |
| GB (1) | GB2353282C (https=) |
| HU (1) | HU230353B1 (https=) |
| NZ (2) | NZ506648A (https=) |
| PL (1) | PL343064A1 (https=) |
| SG (2) | SG141233A1 (https=) |
| SK (1) | SK287538B6 (https=) |
| WO (1) | WO1999049029A1 (https=) |
| ZA (1) | ZA200004507B (https=) |
Families Citing this family (302)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6586661B1 (en) | 1997-06-12 | 2003-07-01 | North Carolina State University | Regulation of quinolate phosphoribosyl transferase expression by transformation with a tobacco quinolate phosphoribosyl transferase nucleic acid |
| US7351578B2 (en) | 1999-12-10 | 2008-04-01 | Invitrogen Corp. | Use of multiple recombination sites with unique specificity in recombinational cloning |
| US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
| AUPP249298A0 (en) * | 1998-03-20 | 1998-04-23 | Ag-Gene Australia Limited | Synthetic genes and genetic constructs comprising same I |
| CN101818145A (zh) | 1998-03-20 | 2010-09-01 | 联邦科学和工业研究组织 | 控制基因表达 |
| US8598332B1 (en) | 1998-04-08 | 2013-12-03 | Bayer Cropscience N.V. | Methods and means for obtaining modified phenotypes |
| CN1202246C (zh) * | 1998-04-08 | 2005-05-18 | 联邦科学和工业研究组织 | 获得修饰表型的方法和措施 |
| US20040214330A1 (en) | 1999-04-07 | 2004-10-28 | Waterhouse Peter Michael | Methods and means for obtaining modified phenotypes |
| AR020078A1 (es) * | 1998-05-26 | 2002-04-10 | Syngenta Participations Ag | Metodo para alterar la expresion de un gen objetivo en una celula de planta |
| US6939712B1 (en) * | 1998-12-29 | 2005-09-06 | Impedagen, Llc | Muting gene activity using a transgenic nucleic acid |
| CA2361201A1 (en) * | 1999-01-28 | 2000-08-03 | Medical College Of Georgia Research Institute, Inc. | Composition and method for in vivo and in vitro attenuation of gene expression using double stranded rna |
| DE19956568A1 (de) | 1999-01-30 | 2000-08-17 | Roland Kreutzer | Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens |
| AU2008202208C1 (en) * | 1999-01-30 | 2014-04-24 | Alnylam Pharmaceuticals, Inc. | Method and medicament for inhibiting the expression of a defined gene |
| KR20070118315A (ko) * | 1999-04-21 | 2007-12-14 | 와이어쓰 | 폴리뉴클레오티드 서열의 기능을 억제하기 위한 조성물 |
| US20040138168A1 (en) * | 1999-04-21 | 2004-07-15 | Wyeth | Methods and compositions for inhibiting the function of polynucleotide sequences |
| KR20010112952A (ko) * | 1999-05-10 | 2001-12-22 | 릴리 엠 씨즐러 스피허, 아네뜨 워너 | 바이러스 유전자 발현의 조절 |
| US6423885B1 (en) | 1999-08-13 | 2002-07-23 | Commonwealth Scientific And Industrial Research Organization (Csiro) | Methods for obtaining modified phenotypes in plant cells |
| ATE383433T1 (de) | 1999-08-26 | 2008-01-15 | Calgene Llc | Pflanzen mit veränderten mehrfachungesättigten fettsäuren |
| US7531718B2 (en) | 1999-08-26 | 2009-05-12 | Monsanto Technology, L.L.C. | Nucleic acid sequences and methods of use for the production of plants with modified polyunsaturated fatty acids |
| US7067722B2 (en) | 1999-08-26 | 2006-06-27 | Monsanto Technology Llc | Nucleic acid sequences and methods of use for the production of plants with modified polyunsaturated fatty acids |
| GB9927444D0 (en) * | 1999-11-19 | 2000-01-19 | Cancer Res Campaign Tech | Inhibiting gene expression |
| DE10100586C1 (de) | 2001-01-09 | 2002-04-11 | Ribopharma Ag | Verfahren zur Hemmung der Expression eines Ziegens |
| US7829693B2 (en) | 1999-11-24 | 2010-11-09 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of a target gene |
| US8202979B2 (en) | 2002-02-20 | 2012-06-19 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid |
| US7491805B2 (en) | 2001-05-18 | 2009-02-17 | Sirna Therapeutics, Inc. | Conjugates and compositions for cellular delivery |
| WO2003070918A2 (en) | 2002-02-20 | 2003-08-28 | Ribozyme Pharmaceuticals, Incorporated | Rna interference by modified short interfering nucleic acid |
| US7833992B2 (en) | 2001-05-18 | 2010-11-16 | Merck Sharpe & Dohme | Conjugates and compositions for cellular delivery |
| US8273866B2 (en) | 2002-02-20 | 2012-09-25 | Merck Sharp & Dohme Corp. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (SINA) |
| EP1272630A2 (en) | 2000-03-16 | 2003-01-08 | Genetica, Inc. | Methods and compositions for rna interference |
| US8202846B2 (en) | 2000-03-16 | 2012-06-19 | Cold Spring Harbor Laboratory | Methods and compositions for RNA interference |
| KR20020097198A (ko) * | 2000-03-17 | 2002-12-31 | 베니텍 오스트레일리아 리미티드 | 유전자 사일런싱 |
| ES2336887T5 (es) | 2000-03-30 | 2019-03-06 | Whitehead Inst Biomedical Res | Mediadores de interferencia por ARN específicos de secuencias de ARN |
| US7198924B2 (en) | 2000-12-11 | 2007-04-03 | Invitrogen Corporation | Methods and compositions for synthesis of nucleic acid molecules using multiple recognition sites |
| EP1724355A3 (en) | 2000-08-30 | 2007-05-23 | North Carolina State University | Transgenic plants containing molecular decoys that alter protein content therein |
| US20080032942A1 (en) | 2000-08-30 | 2008-02-07 | Mcswiggen James | RNA interference mediated treatment of Alzheimer's disease using short interfering nucleic acid (siNA) |
| CA2427347C (en) | 2000-10-31 | 2011-01-18 | Commonwealth Scientific And Industrial Research Organisation | Method and means for producing barley yellow dwarf virus resistant cereal plants |
| JP2004533807A (ja) | 2000-11-07 | 2004-11-11 | ノース・キャロライナ・ステイト・ユニヴァーシティ | プトレッシン−n−メチルトランスフェラーゼプロモーター |
| CA2429814C (en) | 2000-12-01 | 2014-02-18 | Thomas Tuschl | Rna interference mediating small rna molecules |
| US7767802B2 (en) | 2001-01-09 | 2010-08-03 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of anti-apoptotic genes |
| US7423142B2 (en) | 2001-01-09 | 2008-09-09 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of anti-apoptotic genes |
| US8546143B2 (en) | 2001-01-09 | 2013-10-01 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of a target gene |
| EP1354035B1 (en) | 2001-01-26 | 2016-08-24 | Commonwealth Scientific and Industrial Research Organisation | Methods and means for producing efficient silencing construct using recombinational cloning |
| CA2369944A1 (en) | 2001-01-31 | 2002-07-31 | Nucleonics Inc. | Use of post-transcriptional gene silencing for identifying nucleic acid sequences that modulate the function of a cell |
| EP1386004A4 (en) | 2001-04-05 | 2005-02-16 | Ribozyme Pharm Inc | MODULATION OF GENE EXPRESSION ASSOCIATED WITH INFLAMMATORY PROLIFERATION AND GROWTH OF NEURITIES BY METHODS INVOLVING NUCLEIC ACID |
| US7517864B2 (en) | 2001-05-18 | 2009-04-14 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA) |
| US7109165B2 (en) | 2001-05-18 | 2006-09-19 | Sirna Therapeutics, Inc. | Conjugates and compositions for cellular delivery |
| US20050014172A1 (en) | 2002-02-20 | 2005-01-20 | Ivan Richards | RNA interference mediated inhibition of muscarinic cholinergic receptor gene expression using short interfering nucleic acid (siNA) |
| US20050148530A1 (en) | 2002-02-20 | 2005-07-07 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA) |
| US20030175950A1 (en) * | 2001-05-29 | 2003-09-18 | Mcswiggen James A. | RNA interference mediated inhibition of HIV gene expression using short interfering RNA |
| US20050159378A1 (en) | 2001-05-18 | 2005-07-21 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of Myc and/or Myb gene expression using short interfering nucleic acid (siNA) |
| US20050256068A1 (en) | 2001-05-18 | 2005-11-17 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of stearoyl-CoA desaturase (SCD) gene expression using short interfering nucleic acid (siNA) |
| US9994853B2 (en) | 2001-05-18 | 2018-06-12 | Sirna Therapeutics, Inc. | Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference |
| US8008472B2 (en) | 2001-05-29 | 2011-08-30 | Merck Sharp & Dohme Corp. | RNA interference mediated inhibition of human immunodeficiency virus (HIV) gene expression using short interfering nucleic acid (siNA) |
| CA2449920A1 (en) | 2001-06-08 | 2002-12-19 | Vector Tobacco Ltd. | Modifying nicotine and nitrosamine levels in tobacco |
| AUPR621501A0 (en) | 2001-07-06 | 2001-08-02 | Commonwealth Scientific And Industrial Research Organisation | Delivery of ds rna |
| IL159756A0 (en) | 2001-07-12 | 2004-06-20 | Univ Massachusetts | IN VIVO PRODUCTION OF SMALL INTERFERING RNAs THAT MEDIATE GENE SILENCING |
| US10590418B2 (en) | 2001-07-23 | 2020-03-17 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for RNAi mediated inhibition of gene expression in mammals |
| DK2280070T3 (en) | 2001-07-23 | 2015-08-24 | Univ Leland Stanford Junior | Methods and compositions for use in RNAi-mediated inhibition of gene expression in mammals |
| US7612194B2 (en) | 2001-07-24 | 2009-11-03 | Monsanto Technology Llc | Nucleic acid sequences from Diabrotica virgifera virgifera LeConte and uses thereof |
| US20050037989A1 (en) * | 2001-08-27 | 2005-02-17 | Lewis David L. | Inhibition of gene function by delivery of polynucleotide-based gene expression inhibitors to mammalian cells in vivo |
| ATE556714T1 (de) | 2002-02-01 | 2012-05-15 | Life Technologies Corp | Doppelsträngige oligonukleotide |
| US20060009409A1 (en) | 2002-02-01 | 2006-01-12 | Woolf Tod M | Double-stranded oligonucleotides |
| US7662952B2 (en) | 2002-02-20 | 2010-02-16 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of GRB2 associated binding protein (GAB2) gene expression using short interfering nucleic acid (siNA) |
| US7910724B2 (en) | 2002-02-20 | 2011-03-22 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of Fos gene expression using short interfering nucleic acid (siNA) |
| EP1432724A4 (en) | 2002-02-20 | 2006-02-01 | Sirna Therapeutics Inc | RNA inhibition mediated inhibition of MAP KINASE GENES |
| US7897752B2 (en) | 2002-02-20 | 2011-03-01 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of telomerase gene expression using short interfering nucleic acid (siNA) |
| US20090253774A1 (en) | 2002-02-20 | 2009-10-08 | Sirna Therapeutics, Inc. | RNA INTERFERENCE MEDIATED INHIBITION OF PLATELET DERIVED GROWTH FACTOR (PDGF) AND PLATELET DERIVED GROWTH FACTOR RECEPTOR (PDGFR) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| US7678897B2 (en) | 2002-02-20 | 2010-03-16 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of platelet-derived endothelial cell growth factor (ECGF1) gene expression using short interfering nucleic acid (siNA) |
| US7928219B2 (en) | 2002-02-20 | 2011-04-19 | Merck Sharp & Dohme Corp. | RNA interference mediated inhibition of placental growth factor gene expression using short interfering nucleic acid (SINA) |
| US7683165B2 (en) | 2002-02-20 | 2010-03-23 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of interleukin and interleukin receptor gene expression using short interfering nucleic acid (siNA) |
| US7893248B2 (en) | 2002-02-20 | 2011-02-22 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of Myc and/or Myb gene expression using short interfering nucleic acid (siNA) |
| AU2003219833A1 (en) * | 2002-02-20 | 2003-09-09 | Sirna Therapeutics Inc. | RNA INTERFERENCE MEDIATED INHIBITION OF CHROMOSOME TRANSLOCATION GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| US7935812B2 (en) | 2002-02-20 | 2011-05-03 | Merck Sharp & Dohme Corp. | RNA interference mediated inhibition of hepatitis C virus (HCV) expression using short interfering nucleic acid (siNA) |
| EP1474433A4 (en) * | 2002-02-20 | 2005-02-23 | Sirna Therapeutics Inc | TARGET LOCALIZATION TARGETED BY RNA INTERFERENCE AND TARGET VALIDATION WITH SHORT INTERFERING NUCLEIC ACID (siNA) |
| US7667029B2 (en) | 2002-02-20 | 2010-02-23 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of checkpoint kinase-1 (CHK-1) gene expression using short interfering nucleic acid (siNA) |
| US7700760B2 (en) | 2002-02-20 | 2010-04-20 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of vascular cell adhesion molecule (VCAM) gene expression using short interfering nucleic acid (siNA) |
| US7897757B2 (en) | 2002-02-20 | 2011-03-01 | Merck Sharp & Dohme Corp. | RNA interference mediated inhibition of protein tyrosine phosphatase-1B (PTP-1B) gene expression using short interfering nucleic acid (siNA) |
| US7683166B2 (en) | 2002-02-20 | 2010-03-23 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of interleukin and interleukin receptor gene expression using short interfering nucleic acid (siNA) |
| US9657294B2 (en) | 2002-02-20 | 2017-05-23 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
| US7928218B2 (en) | 2002-02-20 | 2011-04-19 | Merck Sharp & Dohme Corp. | RNA interference mediated inhibition of polycomb group protein EZH2 gene expression using short interfering nucleic acid (siNA) |
| US7795422B2 (en) | 2002-02-20 | 2010-09-14 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of hypoxia inducible factor 1 (HIF1) gene expression using short interfering nucleic acid (siNA) |
| US8258288B2 (en) | 2002-02-20 | 2012-09-04 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of respiratory syncytial virus (RSV) expression using short interfering nucleic acid (siNA) |
| US8067575B2 (en) | 2002-02-20 | 2011-11-29 | Merck, Sharp & Dohme Corp. | RNA interference mediated inhibition of cyclin D1 gene expression using short interfering nucleic acid (siNA) |
| US7691999B2 (en) | 2002-02-20 | 2010-04-06 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of NOGO and NOGO receptor gene expression using short interfering nucleic acid (siNA) |
| US8013143B2 (en) | 2002-02-20 | 2011-09-06 | Merck Sharp & Dohme Corp. | RNA interference mediated inhibition of CXCR4 gene expression using short interfering nucleic acid (siNA) |
| US7897753B2 (en) | 2002-02-20 | 2011-03-01 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of XIAP gene expression using short interfering nucleic acid (siNA) |
| US20090099117A1 (en) | 2002-02-20 | 2009-04-16 | Sirna Therapeutics, Inc. | RNA INTERFERENCE MEDIATED INHIBITION OF MYOSTATIN GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| AU2003219817B2 (en) | 2002-02-20 | 2006-08-31 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of hepatitis C virus |
| US20090253773A1 (en) | 2002-02-20 | 2009-10-08 | Sirna Therapeutics, Inc. | RNA INTERFERENCE MEDIATED INHIBITION OF TNF AND TNF RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| US20090192105A1 (en) | 2002-02-20 | 2009-07-30 | Sirna Therapeutics, Inc. | RNA INTERFERENCE MEDIATED INHIBITION OF INTERCELLULAR ADHESION MOLECULE (ICAM) GENE EXPRESSION USING SHORT INTERFERING NUCELIC ACID (siNA) |
| US7928220B2 (en) | 2002-02-20 | 2011-04-19 | Merck Sharp & Dohme Corp. | RNA interference mediated inhibition of stromal cell-derived factor-1 (SDF-1) gene expression using short interfering nucleic acid (siNA) |
| US7667030B2 (en) | 2002-02-20 | 2010-02-23 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of matrix metalloproteinase 13 (MMP13) gene expression using short interfering nucleic acid (siNA) |
| US9181551B2 (en) | 2002-02-20 | 2015-11-10 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
| CA2478910C (en) * | 2002-03-14 | 2012-08-21 | Commonwealth Scientific And Industrial Research Organisation | Methods and means for monitoring and modulating gene silencing |
| US7166771B2 (en) | 2002-06-21 | 2007-01-23 | Monsanto Technology Llc | Coordinated decrease and increase of gene expression of more than one gene using transgenic constructs |
| US7601888B2 (en) | 2002-03-21 | 2009-10-13 | Monsanto Technology L.L.C. | Nucleic acid constructs and methods for producing altered seed oil compositions |
| US7566813B2 (en) | 2002-03-21 | 2009-07-28 | Monsanto Technology, L.L.C. | Nucleic acid constructs and methods for producing altered seed oil compositions |
| US20040180438A1 (en) | 2002-04-26 | 2004-09-16 | Pachuk Catherine J. | Methods and compositions for silencing genes without inducing toxicity |
| US8137910B2 (en) | 2002-05-03 | 2012-03-20 | Duke University | Method of regulating gene expression |
| DE60310944T3 (de) | 2002-08-05 | 2017-08-03 | Silence Therapeutics Gmbh | Weitere neue formen von interferierende rns moleküle |
| US20050042646A1 (en) | 2002-08-05 | 2005-02-24 | Davidson Beverly L. | RNA interference suppresion of neurodegenerative diseases and methods of use thereof |
| US20040241854A1 (en) | 2002-08-05 | 2004-12-02 | Davidson Beverly L. | siRNA-mediated gene silencing |
| US20080274989A1 (en) | 2002-08-05 | 2008-11-06 | University Of Iowa Research Foundation | Rna Interference Suppression of Neurodegenerative Diseases and Methods of Use Thereof |
| WO2004015062A2 (en) | 2002-08-12 | 2004-02-19 | New England Biolabs, Inc. | Methods and compositions relating to gene silencing |
| DK1534819T3 (da) | 2002-08-21 | 2010-04-19 | Revivicor Inc | Griselignende dyr, som mangler enhver ekspression af funktionel alfa-1,3-galactosyltransferase |
| US7923547B2 (en) | 2002-09-05 | 2011-04-12 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
| US20040242518A1 (en) * | 2002-09-28 | 2004-12-02 | Massachusetts Institute Of Technology | Influenza therapeutic |
| WO2004041838A1 (en) * | 2002-11-01 | 2004-05-21 | University Of Massachusetts | Regulation of transcription elongation factors |
| US7078234B2 (en) | 2002-12-18 | 2006-07-18 | Monsanto Technology Llc | Maize embryo-specific promoter compositions and methods for use thereof |
| WO2004087878A2 (en) | 2003-03-28 | 2004-10-14 | Monsanto Technology, Llc | Novel plant promoters for use in early seed development |
| JP2006526394A (ja) * | 2003-06-03 | 2006-11-24 | ベニテック オーストラリア リミテッド | 二本鎖核酸 |
| WO2004108903A2 (en) | 2003-06-06 | 2004-12-16 | Arborgen, Llc | Plant transformation and selection |
| WO2005009346A2 (en) * | 2003-06-24 | 2005-02-03 | Mirus Corporation | Inhibition of gene function by delivery of polynucleotide-based gene expression inhibitors to mammalian cells in vivo |
| JP5183064B2 (ja) * | 2003-07-02 | 2013-04-17 | エムユーエスシー ファウンデイション フォー リサーチ デべロップメント | 甲殻類動物、及び他の無脊椎動物における、dsRNAで誘導された特異的、及び非特異的免疫、及びそこで使用する生物送達媒体 |
| CA2533259C (en) * | 2003-07-21 | 2014-01-28 | Lifecell Corporation | Acellular tissue matrices made from galactose .alpha.-1,3-galactose-deficient tissue |
| CN1871341A (zh) | 2003-08-20 | 2006-11-29 | 悉尼北方和中部海岸区医疗服务系统 | 提高胚胎生存力的方法 |
| IL157538A0 (en) | 2003-08-21 | 2004-03-28 | Bar Ilan Res & Dev Company Ltd | Plant resistant to cytoplasm-feeding parasites |
| WO2005026356A1 (en) * | 2003-09-12 | 2005-03-24 | Commonwealth Scientific And Industrial Research Organisation | Modified gene-silencing nucleic acid molecules and uses thereof |
| WO2005047469A2 (en) | 2003-11-05 | 2005-05-26 | University Of Pittsburgh | PORCINE ISOGLOBOSIDE 3 SYNTHASE PROTEIN, cDNA, GENOMIC ORGANIZATION, AND REGULATORY REGION |
| CA2546853C (en) | 2003-11-21 | 2020-04-21 | Revivicor, Inc. | Use of interfering rna in the production of transgenic animals |
| WO2005054438A2 (en) | 2003-12-01 | 2005-06-16 | Invitrogen Corporation | Nucleic acid molecules containing recombination sites and methods of using the same |
| WO2005060739A1 (en) | 2003-12-24 | 2005-07-07 | G2 Inflammation Pty Ltd | Transgenic non-human mammal comprising a polynucleotide encoding human or humanized c5ar |
| AR047598A1 (es) | 2004-02-10 | 2006-01-25 | Monsanto Technology Llc | Semilla de maiz transgenica con mayor contenido de aminoacidos |
| ATE452188T1 (de) | 2004-02-10 | 2010-01-15 | Sirna Therapeutics Inc | Rna-interferenz-vermittelte hemmung der genexpression unter verwendung multifunktioneller sina (short interfering nucleic acid) |
| US7683237B2 (en) | 2004-02-10 | 2010-03-23 | Monsanto Technology Llc | Maize seed with synergistically enhanced lysine content |
| US20060075515A1 (en) | 2004-08-11 | 2006-04-06 | Luethy Michael H | Enhanced zein reduction in transgenic corn seed |
| US7855323B2 (en) | 2004-02-10 | 2010-12-21 | Monsanto Technology Llc | Recombinant DNA for gene suppression |
| CA2558771C (en) | 2004-03-05 | 2013-01-08 | Benitec, Inc. | Multiple promoter expression cassettes for simultaneous delivery of rnai agents |
| AU2005223617A1 (en) | 2004-03-17 | 2005-09-29 | Revivicor, Inc. | Tissue products from animals lacking functional alpha 1,3 galactosyl transferase |
| US20060041961A1 (en) | 2004-03-25 | 2006-02-23 | Abad Mark S | Genes and uses for pant improvement |
| US8049069B2 (en) | 2004-03-31 | 2011-11-01 | Commonwealth Scientific And Industrial Research Organisation | Genes involved in plant fibre development |
| AU2005244258B2 (en) | 2004-04-09 | 2010-07-01 | Monsanto Technology Llc | Compositions and methods for control of insect infestations in plants |
| CA3056110C (en) | 2004-04-22 | 2020-07-14 | Surinder Pal Singh | Synthesis of long-chain polyunsaturated fatty acids by recombinant cells |
| EP1747022A4 (en) | 2004-04-23 | 2010-03-31 | Univ Columbia | INHIBITION OF HAIRLESS PROTEIN MRNA |
| US10508277B2 (en) | 2004-05-24 | 2019-12-17 | Sirna Therapeutics, Inc. | Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference |
| US20060075522A1 (en) | 2004-07-31 | 2006-04-06 | Jaclyn Cleveland | Genes and uses for plant improvement |
| EP1799029B1 (en) | 2004-10-13 | 2012-05-16 | University Of Georgia Research Foundation, Inc. | Nematode resistant transgenic plants |
| US20100170000A9 (en) | 2004-10-25 | 2010-07-01 | Devgen Nv | Rna constructs |
| ATE556126T1 (de) * | 2004-10-29 | 2012-05-15 | Life Technologies Corp | Funktionalisierte fluoreszierende nanokristalle und verfahren zu deren herstellung und verwendung |
| US8404927B2 (en) * | 2004-12-21 | 2013-03-26 | Monsanto Technology Llc | Double-stranded RNA stabilized in planta |
| EP1831376A1 (en) | 2004-12-28 | 2007-09-12 | Pioneer Hi-Bred International, Inc. | Improved grain quality through altered expression of seed proteins |
| AU2006204997B2 (en) | 2005-01-12 | 2011-09-01 | Monsanto Technology, Llc | Genes and uses for plant improvement |
| ATE530656T1 (de) | 2005-02-23 | 2011-11-15 | Univ North Carolina State | Veränderung des alkaloidgehaltes in tabak durch modifikation spezifischer cytochrome p450 gene. |
| DE202005004135U1 (de) * | 2005-03-11 | 2005-05-19 | Klocke Verpackungs-Service Gmbh | Mehrkomponentenverpackung mit Applikator |
| CA2605068A1 (en) * | 2005-04-15 | 2006-10-26 | The Board Of Regents Of The University Of Texas System | Delivery of sirna by neutral lipid compositions |
| WO2006113743A2 (en) * | 2005-04-18 | 2006-10-26 | Massachusetts Institute Of Technology | Compositions and methods for rna interference with sialidase expression and uses thereof |
| EP1874938B1 (en) | 2005-04-19 | 2012-04-04 | BASF Plant Science GmbH | Starchy-endosperm and/or germinating embryo-specific expression in mono-cotyledonous plants |
| NZ564016A (en) | 2005-05-25 | 2009-08-28 | Pioneer Hi Bred Int | Methods for improving crop plant architecture and yield by introducing recombinant expression cassette |
| EP2281896A3 (en) | 2005-09-16 | 2012-04-11 | deVGen N.V. | Transgenic plant-based methods for plant insect pests using RNAi |
| ATE548459T1 (de) | 2005-09-16 | 2012-03-15 | Monsanto Technology Llc | Verfahren zur genetischen kontrolle von insektenbefall bei pflanzen und zusammensetzungen |
| WO2007039454A1 (en) | 2005-09-20 | 2007-04-12 | Basf Plant Science Gmbh | Methods for controlling gene expression using ta-siran |
| EP1934348B1 (en) | 2005-10-11 | 2018-05-02 | Ben-Gurion University Of The Negev Research And Development Authority | Compositions for silencing the expression of vdac1 and uses thereof |
| EP1947925B1 (en) | 2005-10-20 | 2013-12-25 | Commonwealth Scientific And Industrial Research Organisation | Cereals with altered dormancy |
| JP2009526520A (ja) | 2006-01-17 | 2009-07-23 | バイオレックス セラピュティックス インク | 植物中でのn−グリカンのヒト化及び最適化のための組成物及び方法 |
| WO2007092704A2 (en) | 2006-02-09 | 2007-08-16 | Pioneer Hi-Bred International, Inc. | Genes for enhancing nitrogen utilization efficiency in crop plants |
| WO2007095469A2 (en) | 2006-02-10 | 2007-08-23 | Monsanto Technology Llc | Identification and use of target genes for control of plant parasitic nematodes |
| CN101421406B (zh) | 2006-02-13 | 2016-08-31 | 孟山都技术有限公司 | 用于产生改变的种子油组成的核酸构建体和方法 |
| CN105385679B (zh) | 2006-02-13 | 2020-05-26 | 孟山都技术有限公司 | 选择和稳定dsRNA构建体 |
| FR2898908A1 (fr) | 2006-03-24 | 2007-09-28 | Agronomique Inst Nat Rech | Procede de preparation de cellules aviaires differenciees et genes impliques dans le maintien de la pluripotence |
| AR060523A1 (es) | 2006-04-19 | 2008-06-25 | Pioneer Hi Bred Int | Moleculas de polinucleotidos aislados que corresponden a alelos mutantes y tipo salvaje del gen de maiz d9 y metodos para usarlas |
| US8536429B2 (en) | 2006-07-12 | 2013-09-17 | Commonwealth Scientific And Industrial Research Organisation | Polynucleotides encoding a NAX2 polypeptide and methods for enhancing salinity tolerance in plants |
| WO2008027592A2 (en) * | 2006-08-31 | 2008-03-06 | Monsanto Technology, Llc | Phased small rnas |
| CN101195821A (zh) | 2006-12-04 | 2008-06-11 | 中国科学院上海生命科学研究院 | 利用RNAi技术改良植物抗虫性的方法 |
| BRPI0806321A2 (pt) | 2007-01-10 | 2011-09-06 | Sanofi Aventis | métodos para identificação da estabilidade de metilenoaminas orgánicas na presença de amina oxidase sensìvel à semicarbazida e para determinação do perfil da mesma |
| BRPI0807350A2 (pt) | 2007-02-05 | 2014-05-06 | Univ Singapore | Receptor de quitocina putativa e métodos para uso do mesmo |
| WO2008109432A2 (en) * | 2007-03-02 | 2008-09-12 | The Board Of Regents Of The University Of Texas System | Therapeutic targeting of interleukins using sirna in neutral liposomes |
| EP2129680B1 (en) | 2007-03-21 | 2015-05-06 | Brookhaven Science Associates, LLC | Combined hairpin-antisense compositions and methods for modulating expression |
| WO2008118487A2 (en) * | 2007-03-26 | 2008-10-02 | University Of Massachusetts Medical School | Compositions and methods for incresing immunogenicity of glycoprotein vaccines |
| US20100240597A1 (en) | 2007-06-15 | 2010-09-23 | Arkansas State University | Methods of delivery of molecules to cells using a ricin subunit and compositions relating to same |
| CA2696250C (en) | 2007-08-13 | 2016-12-06 | Commonwealth Scientific And Industrial Research Organisation | Barley with low levels of hordeins |
| AU2008286701B2 (en) | 2007-08-14 | 2015-02-12 | Commonwealth Scientific And Industrial Research Organisation | Improved gene silencing methods |
| US8426565B2 (en) | 2007-08-30 | 2013-04-23 | Walter And Eliza Hall Institute Of Medical Research | Dendritic cell marker and uses thereof |
| CN101932712B (zh) | 2007-11-20 | 2014-05-14 | 先锋国际良种公司 | 用于改善植物应激耐性的玉米乙烯信号转导基因及其调节 |
| JP5695422B2 (ja) | 2007-11-27 | 2015-04-08 | コモンウェルス サイエンティフィック アンド インダストリアル リサーチ オーガナイゼーション | デンプン代謝改変植物 |
| WO2009082208A2 (en) | 2007-12-21 | 2009-07-02 | Keygene N.V. | Trichome specific promoters |
| MX2010010867A (es) * | 2008-04-04 | 2011-05-25 | Robert Shorr | Composicion farmaceutica. |
| ES2525045T3 (es) | 2008-04-24 | 2014-12-16 | Newsouth Innovations Pty Limited | Agrupación de genes de saxitoxina de cianobacterias y detección de organismos cianotóxicos |
| WO2009132351A2 (en) * | 2008-04-25 | 2009-10-29 | University Of Medicine And Dentistry Of New Jersey | Anti-sense microrna expression vectors |
| US8093043B2 (en) | 2008-06-04 | 2012-01-10 | New York University | β-TrCP1, β-TrCP2 and RSK1 or RSK2 inhibitors and methods for sensitizing target cells to apoptosis |
| WO2010005527A1 (en) | 2008-06-30 | 2010-01-14 | Angioblast Systems, Inc. | Treatment of eye diseases and excessive neovascularization using a combined therapy |
| WO2010009499A1 (en) | 2008-07-21 | 2010-01-28 | Commonwealth Scientific And Industrial Research Organisation | Improved cottonseed oil and uses |
| CN107699545A (zh) | 2008-09-29 | 2018-02-16 | 孟山都技术公司 | 大豆转基因时间mon87705及其检测方法 |
| CA2741006A1 (en) | 2008-10-30 | 2010-05-20 | Pioneer Hi-Bred International, Inc. | Manipulation of glutamine synthetases (gs) to improve nitrogen use efficiency and grain yield in higher plants |
| EP2350131B1 (en) | 2008-11-07 | 2017-06-07 | Research Development Foundation | Compositions and methods for the inhibition of cripto/grp78 complex formation and signaling |
| US8734853B2 (en) | 2008-11-17 | 2014-05-27 | University Of North Texas Health Science Center At Fort Worth | HDL particles for delivery of nucleic acids |
| WO2010065437A1 (en) | 2008-12-03 | 2010-06-10 | Research Development Foundation | Modulation of olfml-3 mediated angiogenesis |
| CA2743707A1 (en) | 2008-12-04 | 2010-06-10 | Pioneer Hi-Bred International, Inc. | Methods and compositions for enhanced yield by targeted expression of knotted1 |
| US8497075B2 (en) | 2008-12-09 | 2013-07-30 | Novartis Ag | Methods of identifying a modulator that inhibits the binding between Epstein-Barr virus induced receptor 2 and cholesterol derived ligands |
| US8716553B2 (en) | 2009-03-02 | 2014-05-06 | Pioneer Hi Bred International Inc | NAC transcriptional activators involved in abiotic stress tolerance |
| US9487756B2 (en) | 2009-03-20 | 2016-11-08 | Mesoblast, Inc. | Production of reprogrammed pluripotent cells |
| US20110045080A1 (en) * | 2009-03-24 | 2011-02-24 | William Marsh Rice University | Single-Walled Carbon Nanotube/Bioactive Substance Complexes and Methods Related Thereto |
| CN102395674B (zh) | 2009-04-14 | 2015-07-29 | 先锋国际良种公司 | 调节acc合酶改善低氮条件下的植物产量 |
| EP2419514A4 (en) | 2009-04-17 | 2012-10-24 | Basf Plant Science Co Gmbh | PLANT PROMOTER ABLE TO ACT IN ENDOSPERM AND USES THEREOF |
| CA2759291C (en) | 2009-04-20 | 2020-09-15 | Monsanto Technology Llc | Multiple virus resistance in transgenic tomato plants |
| ES2644055T3 (es) | 2009-06-05 | 2017-11-27 | Centenary Institute Of Cancer Medicine And Cell Biology | Moléculas terapéuticas y de diagnóstico |
| MX336182B (es) | 2009-06-08 | 2016-01-11 | Nunhems Bv | Plantas tolerantes a la sequia. |
| EP2456874A1 (en) | 2009-07-24 | 2012-05-30 | Pioneer Hi-Bred International Inc. | The use of dimerization domain component stacks to modulate plant architecture |
| CN101760555B (zh) * | 2009-09-30 | 2012-06-27 | 西南大学 | 一种基于pcr技术鉴定单拷贝转基因烟草的方法 |
| AR078502A1 (es) | 2009-10-02 | 2011-11-09 | Pioneer Hi Bred Int | Regulacion hacia abajo de acc (acido 1-aminociclopropano-1-carboxilico) sintasa para el rendimiento mejorado de plantas |
| EP3000885B1 (en) | 2009-12-18 | 2018-07-25 | Arrowhead Pharmaceuticals, Inc. | Organic compositions to treat hsf1-related diseases |
| MX2012007855A (es) | 2010-01-06 | 2013-06-05 | Du Pont | Identificacion de ritmos diurnos en tejidos fotosinteticos del zea mays y uso en el mejoramiento de plantas de cultivo. |
| US20120296403A1 (en) | 2010-02-10 | 2012-11-22 | Novartis Ag | Methods and compounds for muscle growth |
| BR112012028848A2 (pt) * | 2010-05-10 | 2018-05-15 | Texas A & M Univ Sys | composições, organismos, sistemas e métodos para expressar um produto de gene em plantas |
| EP2575430A1 (en) | 2010-05-28 | 2013-04-10 | Nunhems B.V. | Plants with increased fruit size |
| EP2593468B1 (en) | 2010-07-12 | 2020-06-10 | The State of Israel, Ministry of Agriculture and Rural Development, Agricultural Research Organization, (A.R.O.), Volcani Center | Isolated polynucleotides and methods and plants using same for regulating plant acidity |
| EP3192880B1 (en) | 2010-08-18 | 2019-10-09 | Fred Hutchinson Cancer Research Center | Nucleic acid agents for use in treating facioscapulohumeral dystrophy (fshd) |
| WO2012027467A1 (en) * | 2010-08-26 | 2012-03-01 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF PROLYL HYDROXYLASE DOMAIN 2 (PHD2) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| EP2633049B1 (en) | 2010-10-27 | 2018-10-10 | Harrisvaccines Inc | Methods and compositions to protect aquatic invertebrates from disease |
| LT3124610T (lt) | 2010-10-28 | 2019-08-12 | Benitec Biopharma Limited | Hbv gydymas |
| WO2012058210A1 (en) | 2010-10-29 | 2012-05-03 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA) |
| ES2950027T3 (es) | 2010-11-04 | 2023-10-04 | Arista Cereal Tech Pty Ltd | Trigo con alto contenido en amilosa |
| NZ609567A (en) | 2010-11-05 | 2015-05-29 | Transbio Ltd | Markers of endothelial progenitor cells and uses thereof |
| ES2680636T3 (es) | 2011-02-14 | 2018-09-10 | Revivicor Inc. | Cerdos genéticamente modificados para xenotrasplante de xenoinjertos vascularizados y derivados de los mismos |
| CA2831144A1 (en) | 2011-03-23 | 2012-09-27 | Pioneer Hi-Bred International, Inc. | Methods for producing a complex transgenic trait locus |
| WO2012148835A1 (en) | 2011-04-29 | 2012-11-01 | Pioneer Hi-Bred International, Inc. | Down-regulation of a homeodomain-leucine zipper i-class homeobox gene for improved plant performance |
| EP2718326B1 (en) | 2011-06-13 | 2020-08-19 | CSL Limited | Antibodies against g-csfr and uses thereof |
| WO2012174139A2 (en) | 2011-06-14 | 2012-12-20 | Synthon Biopharmaceuticals B.V. | Compositions and methods for making and b ioc ont aining auxotrophic transgenic plants |
| CA2844470A1 (en) | 2011-06-21 | 2013-05-10 | Pioneer Hi-Bred International, Inc. | Methods and compositions for producing male sterile plants |
| US20150159166A1 (en) | 2011-10-31 | 2015-06-11 | Pioneer Hi Bred International Inc | Plant drought tolerance and nitrogen use efficiency by reducing plant sensitivity to ethylene |
| WO2013063653A1 (en) | 2011-11-04 | 2013-05-10 | Arista Cereal Technologies Pty Limited | High amylose wheat - ii |
| UA116097C2 (uk) | 2011-12-11 | 2018-02-12 | Зе Стейт Оф Ізраел, Міністрі Оф Агрікалче Енд Руерал Девелопмент, Агрікалчерал Рісьоч Організейшн, (А.Р.О.), Волкані Сентре | Спосіб модуляції провідності устячка рослини |
| US9347067B2 (en) | 2011-12-27 | 2016-05-24 | Commonwealth Scientific And Industrial Research Organisation | Production of dihydrosterculic acid and derivatives thereof |
| AR089442A1 (es) | 2011-12-27 | 2014-08-20 | Commw Scient Ind Res Org | Procesos para producir lipidos |
| EP2798065B1 (en) | 2011-12-27 | 2019-06-05 | Commonwealth Scientific and Industrial Research Organisation | Simultaneous gene silencing and supressing gene silencing in the same cell |
| EP2802658A2 (en) | 2012-01-09 | 2014-11-19 | Novartis AG | Rnai agents to treat beta-catenin related diseases |
| BR112014017196A2 (pt) | 2012-01-11 | 2017-06-13 | The Australian National University | métodos para a modulação ou inibição da modulação da arquitetura da raiz de uma planta, planta, planta transgênica, peptídeo regulador de arquitetura de raiz isolado (rar), polinucleotídeo isolado, vetor recombinante, célula hospedeira transgênica e promotor de planta isolado |
| CN104703998B (zh) | 2012-03-13 | 2020-08-21 | 先锋国际良种公司 | 植物中雄性育性的遗传减少 |
| WO2013138309A1 (en) | 2012-03-13 | 2013-09-19 | Pioneer Hi-Bred International, Inc. | Genetic reduction of male fertility in plants |
| WO2013159149A1 (en) | 2012-04-25 | 2013-10-31 | Commonwealth Scientific And Industrial Research Organisation | High oleic acid oils |
| CN102719454B (zh) * | 2012-06-15 | 2014-07-30 | 华南农业大学 | 一种优化的硫化物醌氧化还原酶基因及其表达载体 |
| EP2885411B1 (en) | 2012-08-16 | 2018-12-05 | VIB vzw | Means and methods for altering the lignin pathway in plants |
| WO2014045126A2 (en) | 2012-09-18 | 2014-03-27 | Uti Limited Partnership | Treatment of pain by inhibition of usp5 de-ubiquitinase |
| CN104955947A (zh) | 2013-01-29 | 2015-09-30 | 格拉斯哥大学董事会 | 用于增加植物中胁迫耐受性和生物量的方法和工具 |
| WO2014134179A1 (en) | 2013-02-28 | 2014-09-04 | The Board Of Regents Of The University Of Texas System | Methods for classifying a cancer as susceptible to tmepai-directed therapies and treating such cancers |
| WO2014164014A1 (en) | 2013-03-11 | 2014-10-09 | Pioneer Hi-Bred International, Inc. | Genes for improving nutrient uptake and abiotic stress tolerance in plants |
| WO2014164116A1 (en) | 2013-03-13 | 2014-10-09 | Pioneer Hi-Bred International, Inc. | Functional expression of bacterial major facilitator superfamily (sfm) gene in maize to improve agronomic traits and grain yield |
| WO2014164074A1 (en) | 2013-03-13 | 2014-10-09 | Pioneer Hi-Bred International, Inc. | Enhanced nitrate uptake and nitrate translocation by over-expressing maize functional low-affinity nitrate transporters in transgenic maize |
| US20160024513A1 (en) | 2013-03-14 | 2016-01-28 | Pioneer Hi-Bred International Inc. | Maize stress related transcription factor 18 and uses thereof |
| WO2014143996A2 (en) | 2013-03-15 | 2014-09-18 | Pioneer Hi-Bred International, Inc. | Compositions and methods of use of acc oxidase polynucleotides and polypeptides |
| CA2904817C (en) | 2013-03-21 | 2022-10-18 | Vib Vzw | Means and methods for the reduction of photorespiration in crops |
| EP2810952A1 (en) | 2013-06-03 | 2014-12-10 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Novel pest control methods |
| AU2014278519B2 (en) | 2013-06-11 | 2020-09-10 | Syngenta Crop Protection Ag | Methods for generating transgenic plants |
| SG11201509675TA (en) | 2013-06-13 | 2015-12-30 | Commw Scient Ind Res Org | Barley with very low levels of hordeins |
| KR20160030099A (ko) | 2013-06-25 | 2016-03-16 | 더 월터 앤드 엘리자 홀 인스티튜트 오브 메디컬 리서치 | 세포내 감염의 치료 방법 |
| EP3057434A4 (en) | 2013-10-16 | 2017-05-03 | The Australian National University | Method for modulating plant growth |
| WO2015066668A1 (en) | 2013-11-04 | 2015-05-07 | Lifecell Corporation | Methods of removing alpha-galactose |
| WO2015069459A1 (en) | 2013-11-05 | 2015-05-14 | Novartis Ag | Organic compounds |
| RU2718054C2 (ru) | 2013-11-28 | 2020-03-30 | СиЭсЭл ЛИМИТЕД | Способ лечения нефропатии |
| WO2015089338A2 (en) | 2013-12-11 | 2015-06-18 | Sloan-Kettering Institute For Cancer Research | Glucocorticoid inhibitors for treatment of prostate cancer |
| WO2015089585A1 (en) | 2013-12-18 | 2015-06-25 | Csl Limited | Method of treating wounds |
| US20170166920A1 (en) | 2014-01-30 | 2017-06-15 | Two Blades Foundation | Plants with enhanced resistance to phytophthora |
| WO2015171723A1 (en) | 2014-05-06 | 2015-11-12 | Research Development Foundation | Methods for treating insulin resistance and for sensitizing patients to glp1 agonist therapy |
| WO2015171603A1 (en) | 2014-05-06 | 2015-11-12 | Two Blades Foundation | Methods for producing plants with enhanced resistance to oomycete pathogens |
| MY178434A (en) | 2014-07-07 | 2020-10-13 | Commw Scient Ind Res Org | Processes for producing industrial products from plant lipids |
| US20170159065A1 (en) | 2014-07-08 | 2017-06-08 | Vib Vzw | Means and methods to increase plant yield |
| WO2016079527A1 (en) | 2014-11-19 | 2016-05-26 | Tetralogic Birinapant Uk Ltd | Combination therapy |
| WO2016094342A1 (en) | 2014-12-08 | 2016-06-16 | The Board Of Regents Of The University Of Texas System | Lipocationic polymers and uses thereof |
| WO2016097773A1 (en) | 2014-12-19 | 2016-06-23 | Children's Cancer Institute | Therapeutic iap antagonists for treating proliferative disorders |
| BR112017025724A2 (pt) | 2015-05-29 | 2018-08-14 | Arcadia Biosciences Inc. | grãos com teor reduzido de glúten e compostos dos mesmos |
| JP2018518184A (ja) | 2015-06-19 | 2018-07-12 | アルカディア バイオサイエンシズ,インコーポレイテッド | リポキシゲナーゼ活性を減退させたコムギ |
| US10000766B2 (en) * | 2015-07-17 | 2018-06-19 | National Chung Hsing University | Recombinant construct, recombinant microorganism, recombinant plant cell and method of providing plant with resistance against DNA virus and RNA virus |
| IL257831B2 (en) | 2015-09-04 | 2025-11-01 | Keygene Nv | Diplosporic garden |
| WO2017048789A1 (en) | 2015-09-14 | 2017-03-23 | The Board Of Regents Of The University Of Texas System | Lipocationic dendrimers and uses thereof |
| WO2017062790A1 (en) | 2015-10-09 | 2017-04-13 | Two Blades Foundation | Cold shock protein receptors and methods of use |
| WO2017083920A1 (en) | 2015-11-18 | 2017-05-26 | Commonwealth Scientific And Industrial Research Organisation | Rice grain with thickened aleurone |
| US10849906B2 (en) | 2015-11-30 | 2020-12-01 | Yanhui Xie | Use of Akt2 in diagnosis and treatment of tumor |
| AU2017234920B2 (en) | 2016-03-18 | 2023-08-17 | E. I. Du Pont De Nemours And Company | Methods and compositions for producing clonal, non-reduced, non-recombined gametes |
| WO2017162265A1 (en) * | 2016-03-21 | 2017-09-28 | Biontech Rna Pharmaceuticals Gmbh | Trans-replicating rna |
| US12185424B2 (en) | 2016-04-20 | 2024-12-31 | Tm Ip Holdings, Llc | Secure routing of data packets including with use with transpositional modulation fortified communications |
| US12133287B1 (en) | 2016-04-20 | 2024-10-29 | Tm Ip Holdings, Llc | Transpositional modulation fortified communications traffic management |
| CN109414408B (zh) | 2016-05-16 | 2022-03-29 | 得克萨斯州大学系统董事会 | 阳离子磺酰胺氨基脂质和两亲性两性离子氨基脂质 |
| EP3500279A4 (en) * | 2016-08-19 | 2020-04-22 | Calimmune, Inc. | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANINE CONDITIONS USING A RECOMBINANT SELF-COMPLEMENTARY ADENO-ASSOCIATED VIRUS. |
| JP7165410B2 (ja) | 2016-08-19 | 2022-11-04 | ユニバーシティ オブ フロリダ リサーチ ファウンデーション,インコーポレイティド | 組換え自己相補的アデノ随伴ウイルスを使用して疾患を治療するための方法及び組成物 |
| CN107841510B (zh) * | 2016-09-20 | 2021-02-09 | 中国科学院青岛生物能源与过程研究所 | 一种原核细胞转录后水平控制不同基因表达比例的方法 |
| KR20190088561A (ko) | 2016-12-07 | 2019-07-26 | 유니버시티 오브 플로리다 리서치 파운데이션, 인코포레이티드 | 인터류킨-1 수용체 길항제(IL-1RA) cDNA |
| US12428641B2 (en) | 2017-09-15 | 2025-09-30 | Commonwealth Scientific And Industrial Research Organisation | RNA molecules |
| US20210179721A1 (en) | 2017-11-29 | 2021-06-17 | Csl Limited | Method of treating or preventing ischemia-reperfusion injury |
| US12281160B2 (en) | 2018-03-23 | 2025-04-22 | Csl Limited | Method of treating asthma |
| EP3775258A4 (en) | 2018-03-28 | 2022-01-26 | Board of Regents, The University of Texas System | IDENTIFICATION OF EPIGENETIC ALTERATIONS IN DNA ISOLATED FROM EXOSOMES |
| US11649455B2 (en) | 2018-03-30 | 2023-05-16 | University Of Geneva | Micro RNA expression constructs and uses thereof |
| CN112888440A (zh) | 2018-10-16 | 2021-06-01 | 豪夫迈·罗氏有限公司 | Akt抑制剂在眼科中的用途 |
| EP3911957A1 (en) | 2019-01-17 | 2021-11-24 | F. Hoffmann-La Roche AG | E3 ubiquitin ligase (ube3a) protein targets |
| US20220136011A1 (en) | 2019-02-08 | 2022-05-05 | Board Of Regents, The University Of Texas System | Telomerase-containing exosomes for treatment of diseases associated with aging and age-related organ dysfunction |
| CA3148950A1 (en) | 2019-07-30 | 2021-02-04 | The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization (A.R.O.), Volcani Center | Methods of controlling cannabinoid synthesis in plants or cells and plants and cells produced thereby |
| EP3825408A1 (en) | 2019-11-19 | 2021-05-26 | FRAUNHOFER-GESELLSCHAFT zur Förderung der angewandten Forschung e.V. | Methods of multi-species insect pest control |
| CN115996707A (zh) | 2020-04-20 | 2023-04-21 | 德克萨斯大学系统董事会 | 生物活性干粉组合物及其制造和使用方法 |
| CN115715295A (zh) | 2020-05-27 | 2023-02-24 | 安逊生物科学股份有限公司 | 将car t细胞重新定向到感兴趣的抗原的衔接分子 |
| US12583929B2 (en) | 2020-06-04 | 2026-03-24 | CSL Innovation Pty Ltd | Method of treating acute respiratory distress syndrome |
| US20230266325A1 (en) | 2020-06-30 | 2023-08-24 | Lunglife Ai, Inc. | Methods for detecting lung cancer |
| EP4284513A1 (en) | 2021-01-26 | 2023-12-06 | Universite Brest Bretagne Occidentale | Novel stim1 splicing variants and uses thereof |
| US20250019717A1 (en) | 2021-08-06 | 2025-01-16 | Kws Vegetables B.V. | Durable downy mildew resistance in spinach |
| WO2023020980A1 (en) | 2021-08-16 | 2023-02-23 | F. Hoffmann-La Roche Ag | E3 ubiquitin ligase (ube3a) protein targets |
| CN116145266B (zh) * | 2021-11-19 | 2025-08-29 | 广东少和生物科技有限公司 | 蛹虫草Ptrpc重叠启动子文库及其应用 |
| GB202206507D0 (en) | 2022-05-04 | 2022-06-15 | Antion Biosciences Sa | Expression construct |
| EP4532772A1 (en) | 2022-05-24 | 2025-04-09 | Lunglife Ai, Inc. | Methods for detecting circulating genetically abnormal cells |
| WO2024028794A1 (en) | 2022-08-02 | 2024-02-08 | Temple Therapeutics BV | Methods for treating endometrial and ovarian hyperproliferative disorders |
| US12587352B2 (en) | 2023-02-03 | 2026-03-24 | Tm Ip Holdings, Llc | Full duplex adaptive array |
| GB202306619D0 (en) | 2023-05-04 | 2023-06-21 | Antion Biosciences Sa | Cell |
| EP4477069A1 (en) | 2023-06-16 | 2024-12-18 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Unreduced clonal gamete formation and polyploid genome design in the solanaceae |
| IL325176A (en) | 2023-07-05 | 2026-02-01 | CSL Innovation Pty Ltd | Methods for treating or preventing a complication of sickle cell disease |
| GB202402745D0 (en) | 2024-02-27 | 2024-04-10 | Antion Biosciences Sa | Cell |
| WO2025248505A1 (en) | 2024-05-31 | 2025-12-04 | Wayne State University | Methods for treating endometrial and ovarian hyperproliferative disorders |
Family Cites Families (229)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US86356A (en) * | 1869-02-02 | Improvement in the construction of fire-proof safes | ||
| US114784A (en) * | 1871-05-16 | Improvement in compounds for cure of chills and fever | ||
| US165894A (en) * | 1875-07-20 | Improvement in vessels for removing foul water from docks | ||
| US27783A (en) * | 1860-04-10 | Improvement in apparatus for evaporating sugar-juices | ||
| US36197A (en) * | 1862-08-12 | Improvement in compound bullets for small-arms | ||
| US266005A (en) * | 1882-10-17 | William allen | ||
| US74684A (en) * | 1868-02-18 | of wallingford | ||
| US56235A (en) * | 1866-07-10 | Improvement in paring-knives | ||
| US3931397A (en) | 1971-11-05 | 1976-01-06 | Beecham Group Limited | Biologically active material |
| US4024222A (en) | 1973-10-30 | 1977-05-17 | The Johns Hopkins University | Nucleic acid complexes |
| US4034323A (en) * | 1975-03-24 | 1977-07-05 | Oki Electric Industry Company, Ltd. | Magnetic relay |
| US4283393A (en) | 1979-03-13 | 1981-08-11 | Merck & Co., Inc. | Topical application of interferon inducers |
| US4469863A (en) | 1980-11-12 | 1984-09-04 | Ts O Paul O P | Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof |
| US4605394A (en) | 1982-12-03 | 1986-08-12 | Simon V. Skurkovich | Methods for the treatment of pathological conditions by removing interferon from the organism |
| DE3208247A1 (de) | 1982-03-08 | 1983-09-22 | Philips Patentverwaltung Gmbh, 2000 Hamburg | Cuvette fuer die atom-absorptions-spektrometrie |
| JPS5936698A (ja) | 1982-08-20 | 1984-02-28 | Science & Tech Agency | B型肝炎ウイルス遺伝子を組込んだ組換えdnaおよび形質転換動物細胞 |
| NZ209840A (en) * | 1983-10-17 | 1988-11-29 | Kaji Akira | A method of inhibiting viral propagation by hybridising dna with the viral rna thus blocking its action |
| US5272065A (en) | 1983-10-20 | 1993-12-21 | Research Foundation Of State University Of New York | Regulation of gene expression by employing translational inhibition of MRNA utilizing interfering complementary MRNA |
| US5190931A (en) * | 1983-10-20 | 1993-03-02 | The Research Foundation Of State University Of New York | Regulation of gene expression by employing translational inhibition of MRNA utilizing interfering complementary MRNA |
| US5208149A (en) * | 1983-10-20 | 1993-05-04 | The Research Foundation Of State University Of New York | Nucleic acid constructs containing stable stem and loop structures |
| DE3486053T3 (de) | 1983-10-20 | 2004-01-08 | The Research Foundation Of State University Of New York | Regulierung von Gen-Expression durch Translationshemmung unter Verwendung von m-RNS hinderndem Komplementär-RNS. |
| US5173410A (en) | 1984-02-15 | 1992-12-22 | Lubrizol Genetics Inc. | Transfer vector |
| US4945050A (en) | 1984-11-13 | 1990-07-31 | Cornell Research Foundation, Inc. | Method for transporting substances into living cells and tissues and apparatus therefor |
| US4766072A (en) | 1985-07-17 | 1988-08-23 | Promega Corporation | Vectors for in vitro production of RNA copies of either strand of a cloned DNA sequence |
| GB8521646D0 (en) | 1985-08-30 | 1985-10-02 | English Clays Lovering Pochin | Inorganic fillers |
| CA1326450C (en) | 1985-08-26 | 1994-01-25 | William A. Carter | Modulation of aids virus-related events by double stranded rnas (dsrnas) |
| US6617496B1 (en) | 1985-10-16 | 2003-09-09 | Monsanto Company | Effecting virus resistance in plants through the use of negative strand RNAs |
| GB8601680D0 (en) | 1986-01-23 | 1986-02-26 | Agricultural Genetics Co | Modification of plant viruses |
| US5453566A (en) | 1986-03-28 | 1995-09-26 | Calgene, Inc. | Antisense regulation of gene expression in plant/cells |
| NZ219472A (en) | 1986-03-28 | 1990-08-28 | Calgene Inc | Regulation of phenotype in plant cells using dsdna constructs |
| US5107065A (en) | 1986-03-28 | 1992-04-21 | Calgene, Inc. | Anti-sense regulation of gene expression in plant cells |
| US5017488A (en) * | 1986-04-01 | 1991-05-21 | University Of Medicine And Dentistry Of New Jersey | Highly efficient dual T7/T3 promoter vector PJKF16 and dual SP6/T3 promoter vector PJFK15 |
| DE3850683T2 (de) * | 1987-02-09 | 1994-10-27 | Lubrizol Genetics Inc | Hybrides RNS-Virus. |
| PH24467A (en) | 1987-03-03 | 1990-07-18 | Hem Res Inc | Synergistics interplay of lymphokines and dsrnas |
| US4950652A (en) | 1987-03-23 | 1990-08-21 | Hem Research, Inc. | dsRNAs for combination therapy in the treatment of viral diseases |
| AU1820588A (en) | 1987-07-17 | 1989-01-19 | Hem Research, Inc. | Double-stranded rna correction of abnormalities in circulating immune complexes and monocyte function |
| IE66830B1 (en) | 1987-08-12 | 1996-02-07 | Hem Res Inc | Topically active compositions of double-stranded RNAs |
| IE72103B1 (en) | 1987-08-12 | 1997-03-12 | Hem Res Inc | Promotion of host defense by systemic dsRNA treatment |
| EP0306347B1 (en) | 1987-09-04 | 1995-05-10 | Hem Pharmaceuticals Corp. | Diagnosis of double-stranded RNA deficiency states |
| US5874555A (en) | 1987-10-30 | 1999-02-23 | California Institute Of Technology | Triple helices and processes for making same |
| US4963532A (en) | 1987-11-25 | 1990-10-16 | Hem Research, Inc. | dsRNA-based prevention of viral escape |
| US5254678A (en) * | 1987-12-15 | 1993-10-19 | Gene Shears Pty. Limited | Ribozymes |
| MC2115A1 (fr) | 1987-12-15 | 1991-07-05 | Gene Shears Pty Ltd | Ribozynes |
| PH25365A (en) | 1987-12-23 | 1991-05-13 | Hem Research | Rhase l inhibitor as a marker for virus infections |
| US5922602A (en) | 1988-02-26 | 1999-07-13 | Biosource Technologies, Inc. | Cytoplasmic inhibition of gene expression |
| GB8810120D0 (en) | 1988-04-28 | 1988-06-02 | Plant Genetic Systems Nv | Transgenic nuclear male sterile plants |
| CA1320446C (en) | 1988-06-20 | 1993-07-20 | William A. Carter | Modulation of lymphokine-resistant cellular states by dsrnas |
| ES2066847T3 (es) | 1988-07-07 | 1995-03-16 | Hem Pharma Corp | Diagnostico y tratamiento del sindrome de fatiga cronica. |
| US5597718A (en) * | 1988-10-04 | 1997-01-28 | Agracetus | Genetically engineering cotton plants for altered fiber |
| US5198346A (en) * | 1989-01-06 | 1993-03-30 | Protein Engineering Corp. | Generation and selection of novel DNA-binding proteins and polypeptides |
| US5780269A (en) * | 1989-02-24 | 1998-07-14 | The University Of Medicine And Denistry Of New Jersey | Hybrid molecules |
| US5434070A (en) * | 1989-02-24 | 1995-07-18 | The University Of Medicine And Dentistry Of New Jersey | Reverse transcriptases from Escherichia coli and Myxococcus xanthus |
| US5405775A (en) * | 1989-02-24 | 1995-04-11 | The University Of Medicine And Dentistry Of New Jersey | Retrons coding for hybrid DNA/RNA molecules |
| US5436141A (en) | 1989-02-24 | 1995-07-25 | University Of Medicine And Dentistry Of New Jersey | Method for synthesizing stable single-stranded CDNA in eukaryotes by means of a bacterial retron and products |
| DE59010432D1 (de) | 1989-03-16 | 1996-09-05 | Boehringer Ingelheim Int | Genetische Einheiten zur Inhibierung der Funktion von RNA |
| US5231020A (en) | 1989-03-30 | 1993-07-27 | Dna Plant Technology Corporation | Genetic engineering of novel plant phenotypes |
| US5034323A (en) | 1989-03-30 | 1991-07-23 | Dna Plant Technology Corporation | Genetic engineering of novel plant phenotypes |
| WO1990012488A2 (en) | 1989-04-05 | 1990-11-01 | The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce | A clone of double-stranded rna virus applied to antibody production, study of retrovirus-like frameshifting and production of proteins in yeast |
| AU5421090A (en) | 1989-04-05 | 1990-11-05 | United States of America, as represented by the Secretary, U.S. Department of Commerce, The | A clone of double-stranded rna virus and applications thereof |
| EP0473576A4 (en) | 1989-05-19 | 1993-03-10 | Hem Research, Inc. | Short therapeutic dsrna of defined structure |
| US5122466A (en) | 1989-06-13 | 1992-06-16 | North Carolina State University | Ballistic transformation of conifers |
| GB8916213D0 (en) | 1989-07-14 | 1989-08-31 | Ici Plc | Dna constructs,cells and plants derived therefrom |
| WO1991002069A1 (en) | 1989-08-10 | 1991-02-21 | Plant Genetic Systems N.V. | Plants with modified flowers |
| US5747308A (en) | 1989-10-25 | 1998-05-05 | Celltech Therapeutics Limited | Recombinant DNA method |
| US5939600A (en) * | 1989-11-03 | 1999-08-17 | Goldbach; Robert Willem | Nucleic acids encoding tospovirus genome and expression thereof |
| HUT57265A (en) * | 1989-11-03 | 1991-11-28 | Zaadunie Bv | Process for producing plants of diminished infection-sensitivity |
| US5457189A (en) * | 1989-12-04 | 1995-10-10 | Isis Pharmaceuticals | Antisense oligonucleotide inhibition of papillomavirus |
| US5578718A (en) * | 1990-01-11 | 1996-11-26 | Isis Pharmaceuticals, Inc. | Thiol-derivatized nucleosides |
| AU642959B2 (en) * | 1990-01-18 | 1993-11-04 | United States of America, as represented by the Secretary, U.S. Department of Commerce, The | Vector with multiple target response elements affecting gene expression |
| US6245560B1 (en) * | 1990-01-18 | 2001-06-12 | The United States Of America As Represented By The Department Of Health And Human Services | Vector with multiple target response elements affecting gene expression |
| US5168064A (en) | 1990-04-20 | 1992-12-01 | The Regents Of The University Of California | Endo-1,4-β-glucanase gene and its use in plants |
| GB9009307D0 (en) | 1990-04-25 | 1990-06-20 | Ici Plc | Dna,constructs,cells and plant derived therefrom |
| WO1991018088A1 (en) * | 1990-05-23 | 1991-11-28 | The United States Of America, Represented By The Secretary, United States Department Of Commerce | Adeno-associated virus (aav)-based eucaryotic vectors |
| US5270163A (en) * | 1990-06-11 | 1993-12-14 | University Research Corporation | Methods for identifying nucleic acid ligands |
| AU8059891A (en) | 1990-06-13 | 1992-01-07 | Trustees Of Princeton University, The | A (lac) repressor-hsv vp16 chimeric transcriptional activator protein system functioning in transfected mammalian cells |
| HUT69956A (en) | 1990-08-14 | 1995-09-28 | Isis Pharmaceuticals Inc | Methode for inhibition of influenza virus by antiseuse oligonucleotides |
| DE4027616A1 (de) * | 1990-08-31 | 1992-03-05 | Boehringer Mannheim Gmbh | Verfahren zur bestimmung von polymerase-aktivitaet |
| MX9100993A (es) | 1990-09-10 | 1992-05-04 | Us Agriculture | Secuencia de adn aislado y enzima acido 1-aminociclopropan-1-carboxilico sintasa,recombinante |
| US5306862A (en) * | 1990-10-12 | 1994-04-26 | Amoco Corporation | Method and composition for increasing sterol accumulation in higher plants |
| SE9004095L (sv) | 1990-12-21 | 1992-06-01 | Amylogene Hb | Genetisk foeraendring av potatis foer bildning av staerkelse av amylostyp |
| SE467358B (sv) | 1990-12-21 | 1992-07-06 | Amylogene Hb | Genteknisk foeraendring av potatis foer bildning av staerkelse av amylopektintyp |
| EP0568641A4 (en) | 1991-01-25 | 1994-09-14 | Us Biochemical Corp | Regulation of nucleic acid translation |
| GB9105383D0 (en) * | 1991-03-14 | 1991-05-01 | Immunology Ltd | An immunotherapeutic for cervical cancer |
| GB9106713D0 (en) | 1991-03-28 | 1991-05-15 | Ici Plc | Dna,dna constructs,cells and plants derived therefrom |
| IE921206A1 (en) | 1991-04-16 | 1992-10-21 | Mogen Int | Male-sterile plants, method for obtaining male-sterile¹plants and recombinant dna for use therein |
| CA2106386A1 (en) | 1991-04-18 | 1992-10-19 | Barbara C. F. Chu | Oligodeoxynucleotides and oligonucleotides useful as decoys for proteins which selectively bind to defined dna sequences |
| FR2675803B1 (fr) | 1991-04-25 | 1996-09-06 | Genset Sa | Oligonucleotides fermes, antisens et sens et leurs applications. |
| GB9109063D0 (en) | 1991-04-26 | 1991-06-12 | Ici Plc | Modification of lignin synthesis in plants |
| CA2110169A1 (en) | 1991-05-30 | 1992-12-10 | Walter Van Der Eycken | Nematode-responsive plant promoters |
| PL170326B1 (pl) | 1991-07-11 | 1996-11-29 | Int Flower Dev Pty Ltd | S posób wytwarzania rosliny transgenicznej PL |
| US6010908A (en) | 1992-08-21 | 2000-01-04 | The Regents Of The University Of California | Gene therapy by small fragment homologous replacement |
| CA2073630C (en) | 1991-08-30 | 2007-12-11 | Atsushi Ohshima | Method for synthesizing single-stranded stem-loop dnas, the products and uses therefor |
| US5714323A (en) | 1991-08-30 | 1998-02-03 | The University Of Medecine And Dentistry Of New Jersey | Over expression of single-stranded molecules |
| WO1993010251A1 (en) | 1991-11-20 | 1993-05-27 | Mogen International N.V. | A method for obtaining plants with reduced susceptibility to plant-parasitic nematodes |
| FR2685346B1 (fr) * | 1991-12-18 | 1994-02-11 | Cis Bio International | Procede de preparation d'arn double-brin, et ses applications. |
| CA2130454C (en) | 1992-02-19 | 2008-04-08 | William G. Dougherty | Production of viral resistant plants via introduction of untranslatable plus sense viral rna |
| DE4208107A1 (de) | 1992-03-13 | 1993-09-16 | Bayer Ag | Pseudorabies-virus (prv)-polynukleotide und ihre verwendung zur herstellung von virusresistenten eukaryotischen zellen |
| US5593874A (en) * | 1992-03-19 | 1997-01-14 | Monsanto Company | Enhanced expression in plants |
| US5496698A (en) * | 1992-08-26 | 1996-03-05 | Ribozyme Pharmaceuticals, Inc. | Method of isolating ribozyme targets |
| GB9210273D0 (en) | 1992-05-13 | 1992-07-01 | Ici Plc | Dna |
| US5693535A (en) | 1992-05-14 | 1997-12-02 | Ribozyme Pharmaceuticals, Inc. | HIV targeted ribozymes |
| US6451603B1 (en) * | 1992-06-29 | 2002-09-17 | Gene Shears Pty. Limited | Ribozyme nucleic acids and methods of use thereof for controlling viral pathogens |
| PL172710B1 (pl) | 1992-07-02 | 1997-11-28 | Hybridon Inc | Samostabilizujacy sie oligonukleotyd PL PL |
| WO1994003607A1 (en) | 1992-07-30 | 1994-02-17 | Keygene N.V. | Dna constructs, cells and plants derived therefrom |
| CA2106260A1 (en) * | 1992-09-17 | 1994-03-18 | Robert M. Kotin | Human adeno-associated virus integration site dna and uses thereof |
| WO1994007367A1 (en) | 1992-09-29 | 1994-04-14 | Apollon, Inc. | Anti-viral oligomers that bind polypurine tracts of single-stranded rna or rna-dna hybrids |
| CA2146113A1 (en) | 1992-10-15 | 1994-10-15 | Adrianus Johannes Van Tunen | Genetic moderation of restoration or plant phenotypes |
| US6872872B1 (en) * | 1992-11-17 | 2005-03-29 | E. I. Du Pont De Nemours And Company | Genes for microsomal delta-12 fatty acid desaturases and related enzymes from plants |
| US6372965B1 (en) | 1992-11-17 | 2002-04-16 | E.I. Du Pont De Nemours And Company | Genes for microsomal delta-12 fatty acid desaturases and hydroxylases from plants |
| ZA939767B (en) | 1993-01-21 | 1994-09-14 | Univ North Carolina State | Nematode-resistant transgenic plants |
| US6069298A (en) | 1993-02-05 | 2000-05-30 | Regents Of The University Of Minnesota | Methods and an acetyl CoA carboxylase gene for conferring herbicide tolerance and an alteration in oil content of plants |
| JPH08506490A (ja) | 1993-02-05 | 1996-07-16 | モンサント・カンパニー | 植物中の改変リノレン酸及びリノール酸含量 |
| EP0620281A3 (en) * | 1993-03-31 | 1995-05-03 | Mitsubishi Corp | Oilseed-producing oilseeds with modified amino and fatty acid compositions. |
| EP0701619A1 (en) | 1993-06-08 | 1996-03-20 | Nunhems Zaden Bv | Process for generating male sterile plants |
| US5739309A (en) | 1993-07-19 | 1998-04-14 | Gen-Probe Incorporated | Enhancement of oligonucleotide inhibition of protein production, cell proliferation and / or multiplication of infectious disease pathogens |
| JPH09500787A (ja) | 1993-07-19 | 1997-01-28 | ジェン−プローブ・インコーポレイテッド | 蛋白生産、細胞増殖および/または感染症病原体の増殖に対するオリゴヌクレオチド阻害の促進 |
| CA2105364A1 (en) | 1993-09-01 | 1995-03-02 | Eric T. Kool | Stem-loop oligonucleotides containing parallel and antiparallel binding domains |
| US5808036A (en) | 1993-09-01 | 1998-09-15 | Research Corporation Technologies Inc. | Stem-loop oligonucleotides containing parallel and antiparallel binding domains |
| EP0759170B1 (en) | 1993-09-10 | 2008-07-09 | The Trustees Of Columbia University In The City Of New York | Uses of green fluorescent protein |
| GB9318927D0 (en) | 1993-09-13 | 1993-10-27 | Zeneca Ltd | Regulation of senescence |
| JP2001505401A (ja) | 1993-09-20 | 2001-04-24 | シー. リード,ジョン | bc1−2遺伝子発現の調節 |
| US5858981A (en) | 1993-09-30 | 1999-01-12 | University Of Pennsylvania | Method of inhibiting phagocytosis |
| GB9320548D0 (en) | 1993-10-06 | 1993-11-24 | Sandoz Ltd | Improvements in or relating to organic compounds |
| US5624803A (en) | 1993-10-14 | 1997-04-29 | The Regents Of The University Of California | In vivo oligonucleotide generator, and methods of testing the binding affinity of triplex forming oligonucleotides derived therefrom |
| US5801154A (en) * | 1993-10-18 | 1998-09-01 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of multidrug resistance-associated protein |
| US5578716A (en) | 1993-12-01 | 1996-11-26 | Mcgill University | DNA methyltransferase antisense oligonucleotides |
| US5908779A (en) | 1993-12-01 | 1999-06-01 | University Of Connecticut | Targeted RNA degradation using nuclear antisense RNA |
| FR2714383B1 (fr) | 1993-12-29 | 1996-02-09 | Centre Nat Rech Scient | Contrôle de l'expression de gènes. |
| ATE320487T1 (de) | 1994-01-05 | 2006-04-15 | Gene Shears Pty Ltd | Ribozyme gegen eine hiv tat sequenz |
| US5849991A (en) * | 1994-01-27 | 1998-12-15 | Bresatch Limited | Mice homozygous for an inactivated α 1,3-galactosyl transferase gene |
| EP0746614A1 (en) | 1994-02-23 | 1996-12-11 | Ribozyme Pharmaceuticals, Inc. | Method and reagent for inhibiting the expression of disease related genes |
| US5686649A (en) | 1994-03-22 | 1997-11-11 | The Rockefeller University | Suppression of plant gene expression using processing-defective RNA constructs |
| US5631148A (en) | 1994-04-22 | 1997-05-20 | Chiron Corporation | Ribozymes with product ejection by strand displacement |
| US6054299A (en) * | 1994-04-29 | 2000-04-25 | Conrad; Charles A. | Stem-loop cloning vector and method |
| US6146886A (en) | 1994-08-19 | 2000-11-14 | Ribozyme Pharmaceuticals, Inc. | RNA polymerase III-based expression of therapeutic RNAs |
| AU7954794A (en) | 1994-09-12 | 1996-03-29 | City Of Hope | Modulation of drug radiation resistant genes |
| US5576716A (en) * | 1994-12-07 | 1996-11-19 | Sadler; Kermit M. | Owner oriented system for locating lost or stolen property |
| WO1996035706A1 (en) | 1995-05-11 | 1996-11-14 | Hybridon, Inc. | Pyrimidine targeting hairpin triplex-forming oligonucleotides |
| US5691140A (en) | 1995-05-18 | 1997-11-25 | New England Biolabs, Inc. | Bidirectional in vitro transcription vectors utilizing a single RNA polymerase for both directions |
| US5693773A (en) | 1995-06-07 | 1997-12-02 | Hybridon Incorporated | Triplex-forming antisense oligonucleotides having abasic linkers targeting nucleic acids comprising mixed sequences of purines and pyrimidines |
| AU710874B2 (en) | 1995-06-30 | 1999-09-30 | Dna Plant Technology Corporation | Delayed ripening tomato plants |
| FR2737501B1 (fr) * | 1995-07-31 | 1997-10-24 | Transgene Sa | Nouveaux virus auxiliaires pour la preparation de vecteurs viraux recombinants |
| EP0850318A1 (en) | 1995-09-13 | 1998-07-01 | Chiron Corporation | Method and construct for screening for inhibitors of transcriptional activation |
| CA2239976A1 (en) | 1995-09-20 | 1997-03-27 | Paul A. Zamecnik | Antisense oligonucleotide chemotherapy for benign hyperplasia or cancer of the prostate |
| JPH11513256A (ja) | 1995-10-06 | 1999-11-16 | プラント ジエネテイツク システムズ エヌ.ブイ | 種子粉砕 |
| JPH09110894A (ja) | 1995-10-17 | 1997-04-28 | Soyaku Gijutsu Kenkyusho:Kk | ハイブリッドdna/rnaオリゴヌクレオチド及び抗ウイルス剤 |
| EP0771878A1 (en) | 1995-10-31 | 1997-05-07 | Plant Genetic Systems N.V. | Plants with reduced glucosinolate content |
| US5773692A (en) | 1995-12-12 | 1998-06-30 | Her Majesty The Queen In Right Of Canada, As Represented By Agriculture And Agri-Food Canada | Anti-sense RNA for CAB transcript to reduce chlorophyll content in plants |
| CA2279673A1 (en) | 1995-12-15 | 1997-06-16 | Enzo Therapeutics, Inc. | Property effecting and/or property exhibiting constructs for the expression of non-native nucleic acids for therapeutic and diagnostic uses |
| IT1283876B1 (it) | 1996-01-12 | 1998-05-07 | Univ Roma | Molecole chimeriche ribozima-snrna ad attivita' catalitica per rna a localizzazione nucleare |
| EP0880598A4 (en) * | 1996-01-23 | 2005-02-23 | Affymetrix Inc | RAPID EVALUATION OF NUCLEIC ACID ABUNDANCE DIFFERENCE, WITH A HIGH-DENSITY OLIGONUCLEOTIDE SYSTEM |
| US5891855A (en) * | 1996-02-12 | 1999-04-06 | The Scripps Research Institute | Inhibitors of leaderless protein export |
| JP3847366B2 (ja) | 1996-02-22 | 2006-11-22 | アンジェスMg株式会社 | アンチセンスオリゴヌクレオチドを用いた固定性分裂終了細胞増殖剤 |
| US5989864A (en) * | 1996-10-29 | 1999-11-23 | Smithkline Beecham Corporation | DNA encoding spo-rel polypeptides |
| US6153815A (en) | 1996-03-13 | 2000-11-28 | National Research Council Of Canada | DNA sequences from brassicaceae encoding squalene epoxidase and process of raising squalene levels in plants therewith |
| US6413735B1 (en) * | 1996-03-15 | 2002-07-02 | Munin Corporation | Method of screening for a modulator of angiogenesis |
| US6022863A (en) | 1996-05-21 | 2000-02-08 | Yale University | Regulation of gene expression |
| ES2258793T5 (es) | 1996-05-24 | 2010-01-25 | Biogen Idec Ma Inc. | Moduladores de la regeneracion tisular. |
| AU725002B2 (en) | 1996-06-21 | 2000-10-05 | Plant Genetic Systems N.V. | Gene expression in plants |
| US5994526A (en) | 1996-06-21 | 1999-11-30 | Plant Genetic Systems | Gene expression in plants |
| US5952546A (en) * | 1996-06-27 | 1999-09-14 | Dna Plant Technology Corporation | Delayed ripening tomato plants with T-DNA bearing a truncated ACC2 synthase gene |
| US5850026A (en) | 1996-07-03 | 1998-12-15 | Cargill, Incorporated | Canola oil having increased oleic acid and decreased linolenic acid content |
| CA2259179C (en) | 1996-07-03 | 2008-09-23 | University Of Pittsburgh | Emulsion formulations for hydrophilic active agents |
| NZ333802A (en) * | 1996-08-02 | 2001-09-28 | Genesense Technologies Inc | Antitumor antisense sequences directed against R1 and R2 components of ribonucleotide reductase |
| DE19631919C2 (de) | 1996-08-07 | 1998-07-16 | Deutsches Krebsforsch | Anti-Sinn-RNA mit Sekundärstruktur |
| US5747338A (en) | 1996-08-15 | 1998-05-05 | Chiron Corporation | Method and construct for screening for inhibitors of transcriptional activation |
| US6225290B1 (en) | 1996-09-19 | 2001-05-01 | The Regents Of The University Of California | Systemic gene therapy by intestinal cell transformation |
| US5814500A (en) | 1996-10-31 | 1998-09-29 | The Johns Hopkins University School Of Medicine | Delivery construct for antisense nucleic acids and methods of use |
| GB9703146D0 (en) | 1997-02-14 | 1997-04-02 | Innes John Centre Innov Ltd | Methods and means for gene silencing in transgenic plants |
| CN1248292A (zh) | 1997-02-21 | 2000-03-22 | 丹尼斯科有限公司 | 淀粉分支酶表达的反义内含子的抑制作用 |
| EP0921195A1 (en) * | 1997-03-10 | 1999-06-09 | Japan Tobacco Inc. | Antisense base sequences |
| GB9706381D0 (en) | 1997-03-27 | 1997-05-14 | Cambridge Advanced Tech | Improvements relating to the specificity of gene expression |
| US7589253B2 (en) | 1997-04-15 | 2009-09-15 | Commonwealth Scientific And Industrial Research Organisation | Fatty acid epoxygenase genes from plants and uses therefor in modifying fatty acid metabolism |
| US5942395A (en) | 1997-05-09 | 1999-08-24 | Universite De Montreal | Hybrid ribozymes and methods of use |
| GB9710475D0 (en) | 1997-05-21 | 1997-07-16 | Zeneca Ltd | Gene silencing |
| EP1019429A4 (en) * | 1997-08-20 | 2001-08-08 | Somagenics Inc | ANTISENSE THERAPEUTIC PRODUCTS WITH IMPROVED BINDING PROPERTIES AND METHODS OF USE |
| GB9720148D0 (en) | 1997-09-22 | 1997-11-26 | Innes John Centre Innov Ltd | Gene silencing materials and methods |
| CA2309719A1 (en) | 1997-11-18 | 1999-05-27 | Pioneer Hi-Bred International, Inc. | Targeted manipulation of genes in plants |
| DE19754622A1 (de) | 1997-12-09 | 1999-06-10 | Antje Von Dr Schaewen | Pflanzliche GntI-Sequenzen und Verwendung derselben zur Gewinnung von Pflanzen mit verminderter oder fehlender N-Acetylglucosaminyltransferase I (GnTI)-Aktivität |
| US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
| AUPP249298A0 (en) | 1998-03-20 | 1998-04-23 | Ag-Gene Australia Limited | Synthetic genes and genetic constructs comprising same I |
| CN101818145A (zh) | 1998-03-20 | 2010-09-01 | 联邦科学和工业研究组织 | 控制基因表达 |
| CN1202246C (zh) | 1998-04-08 | 2005-05-18 | 联邦科学和工业研究组织 | 获得修饰表型的方法和措施 |
| US8598332B1 (en) | 1998-04-08 | 2013-12-03 | Bayer Cropscience N.V. | Methods and means for obtaining modified phenotypes |
| US20040214330A1 (en) | 1999-04-07 | 2004-10-28 | Waterhouse Peter Michael | Methods and means for obtaining modified phenotypes |
| EP0959133A1 (en) | 1998-05-22 | 1999-11-24 | Centrum Voor Plantenveredelings- En Reproduktieonderzoek (Cpro-Dlo) | A process for inhibiting expression of genes |
| AR020078A1 (es) | 1998-05-26 | 2002-04-10 | Syngenta Participations Ag | Metodo para alterar la expresion de un gen objetivo en una celula de planta |
| GB9827152D0 (en) | 1998-07-03 | 1999-02-03 | Devgen Nv | Characterisation of gene function using double stranded rna inhibition |
| US6040908A (en) * | 1998-07-28 | 2000-03-21 | Litton Systems, Inc. | Method for stress tuning fiber optic sensor coils |
| CA2361201A1 (en) | 1999-01-28 | 2000-08-03 | Medical College Of Georgia Research Institute, Inc. | Composition and method for in vivo and in vitro attenuation of gene expression using double stranded rna |
| DE19956568A1 (de) | 1999-01-30 | 2000-08-17 | Roland Kreutzer | Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens |
| ES2316363T3 (es) | 1999-04-20 | 2009-04-16 | Bayer Bioscience N.V. | Metodos para administracion de rna inhibidor a las plantas y aplicaciones de los mismos. |
| US20040138168A1 (en) | 1999-04-21 | 2004-07-15 | Wyeth | Methods and compositions for inhibiting the function of polynucleotide sequences |
| KR20070118315A (ko) | 1999-04-21 | 2007-12-14 | 와이어쓰 | 폴리뉴클레오티드 서열의 기능을 억제하기 위한 조성물 |
| CA2373628A1 (en) | 1999-06-14 | 2000-12-21 | Michael A. Costa | Animal models and methods for analysis of lipid metabolism and screening of pharmaceutical and pesticidal agents that modulate lipid metabolism |
| BR0012325A (pt) | 1999-07-09 | 2002-05-21 | American Home Prod | Métodos e composições para prevenção da formação de rna anormal durante a transcrição de uma sequência de plasmìdeo |
| US6423885B1 (en) | 1999-08-13 | 2002-07-23 | Commonwealth Scientific And Industrial Research Organization (Csiro) | Methods for obtaining modified phenotypes in plant cells |
| AU7487300A (en) | 1999-09-16 | 2001-04-17 | Genoptera, Llc | Lethal insectidice targets |
| HK1047109A1 (zh) | 1999-10-15 | 2003-02-07 | University Of Massachusetts | 作为指定基因干预工具的rna干预轨迹基因 |
| US6291504B1 (en) | 1999-10-20 | 2001-09-18 | Dupont Pharmaceuticals Company | Acylsemicarbazides and their uses |
| GB9925459D0 (en) | 1999-10-27 | 1999-12-29 | Plant Bioscience Ltd | Gene silencing |
| GB9927444D0 (en) | 1999-11-19 | 2000-01-19 | Cancer Res Campaign Tech | Inhibiting gene expression |
| AU2047001A (en) | 1999-11-24 | 2001-06-04 | Dna Plant Technology Corporation | Methods of inhibiting plant parasitic nematodes and insect pests by expression of nematode and insect specific double-stranded rna in plants |
| WO2001038359A2 (en) | 1999-11-29 | 2001-05-31 | Genoptera, Llc | Drosophila nicotinic acetylcholine receptor |
| GB9930691D0 (en) | 1999-12-24 | 2000-02-16 | Devgen Nv | Improvements relating to double-stranded RNA inhibition |
| KR20020097198A (ko) | 2000-03-17 | 2002-12-31 | 베니텍 오스트레일리아 리미티드 | 유전자 사일런싱 |
| ES2336887T5 (es) | 2000-03-30 | 2019-03-06 | Whitehead Inst Biomedical Res | Mediadores de interferencia por ARN específicos de secuencias de ARN |
| GB2362383B (en) | 2000-05-19 | 2003-12-31 | Devgen Nv | Gene expression system |
| US6995258B1 (en) * | 2000-05-25 | 2006-02-07 | City Of Hope | Nucleolar targeting of therapeutics against HIV |
| JP2004512020A (ja) | 2000-06-23 | 2004-04-22 | イー・アイ・デュポン・ドウ・ヌムール・アンド・カンパニー | 組換え構築物ならびにこれを遺伝子発現を減少させる際に用いる方法 |
| US7109393B2 (en) | 2000-08-15 | 2006-09-19 | Mendel Biotechnology, Inc. | Methods of gene silencing using inverted repeat sequences |
| CA2429814C (en) | 2000-12-01 | 2014-02-18 | Thomas Tuschl | Rna interference mediating small rna molecules |
| US20020150968A1 (en) * | 2001-01-10 | 2002-10-17 | Wang Peng G. | Glycoconjugate and sugar nucleotide synthesis using solid supports |
| CA2369944A1 (en) | 2001-01-31 | 2002-07-31 | Nucleonics Inc. | Use of post-transcriptional gene silencing for identifying nucleic acid sequences that modulate the function of a cell |
| AUPR621501A0 (en) | 2001-07-06 | 2001-08-02 | Commonwealth Scientific And Industrial Research Organisation | Delivery of ds rna |
| IL159756A0 (en) | 2001-07-12 | 2004-06-20 | Univ Massachusetts | IN VIVO PRODUCTION OF SMALL INTERFERING RNAs THAT MEDIATE GENE SILENCING |
| JP4344858B2 (ja) | 2001-09-13 | 2009-10-14 | カリフォルニア インスティチュート オブ テクノロジー | 細胞内で抗ウイルス性小rna分子を発現させる方法 |
| JP2005502383A (ja) | 2001-09-27 | 2005-01-27 | ティモシー アルバート ホルトン | 核酸ライブラリーを作製する方法 |
| US20030148519A1 (en) * | 2001-11-14 | 2003-08-07 | Engelke David R. | Intracellular expression and delivery of siRNAs in mammalian cells |
| GB0130955D0 (en) | 2001-12-24 | 2002-02-13 | Cancer Res Ventures | Expression system |
| US20040022748A1 (en) | 2002-03-12 | 2004-02-05 | Unilever Home & Personal Care Usa, Division Of Conopco, Inc. | Method of enhancing skin lightening |
| CA2478904A1 (en) | 2002-03-14 | 2003-09-18 | Commonwealth Scientific And Industrial Research Organisation | Modified gene-silencing rna and uses thereof |
| ITRM20020253A1 (it) | 2002-05-08 | 2003-11-10 | Univ Roma | Molecole chimeriche di snrna con sequenze antisenso per le giunzioni di splicing del gene della distrofina e applicazioni terapeutiche. |
| US20040106566A1 (en) * | 2002-05-17 | 2004-06-03 | Shi-Lung Lin | RNA-splicing and processing-directed gene silencing and the relative applications thereof |
| AU2003297474A1 (en) * | 2002-12-18 | 2004-07-14 | Salk Institute For Biological Studies | Methods of inhibiting gene expression by rna interference |
| CN1750752A (zh) | 2003-02-19 | 2006-03-22 | 联邦科学和工业研究组织 | 使用短dsRNA序列在植物中进行有效的基因沉默 |
| WO2005026356A1 (en) | 2003-09-12 | 2005-03-24 | Commonwealth Scientific And Industrial Research Organisation | Modified gene-silencing nucleic acid molecules and uses thereof |
| CA2650861A1 (en) | 2006-05-03 | 2007-11-15 | Commonwealth Scientific And Industrial Research Organisation | Improved gene silencing methods |
| WO2009109937A1 (en) * | 2008-03-05 | 2009-09-11 | Nxp B.V. | Dynamic mbsfn area configuration method in consideration of radio resource efficiency and system thereof |
-
1999
- 1999-03-19 CN CN200910206175A patent/CN101818145A/zh active Pending
- 1999-03-19 EP EP10183258.2A patent/EP2302057B1/en not_active Expired - Lifetime
- 1999-03-19 ES ES04015041T patent/ES2374290T3/es not_active Expired - Lifetime
- 1999-03-19 AT AT05013010T patent/ATE526406T1/de not_active IP Right Cessation
- 1999-03-19 SK SK1372-2000A patent/SK287538B6/sk not_active IP Right Cessation
- 1999-03-19 HU HU0101225A patent/HU230353B1/hu unknown
- 1999-03-19 SG SG200503921-9A patent/SG141233A1/en unknown
- 1999-03-19 GB GB0024727A patent/GB2353282C/en not_active Expired - Lifetime
- 1999-03-19 CA CA002487328A patent/CA2487328A1/en not_active Abandoned
- 1999-03-19 JP JP2000537990A patent/JP4187413B2/ja not_active Expired - Lifetime
- 1999-03-19 KR KR1020007010419A patent/KR20010042069A/ko not_active Ceased
- 1999-03-19 KR KR1020107006892A patent/KR101054060B1/ko not_active Expired - Lifetime
- 1999-03-19 ES ES05013010T patent/ES2374534T3/es not_active Expired - Lifetime
- 1999-03-19 KR KR1020067005341A patent/KR101085210B1/ko not_active Expired - Lifetime
- 1999-03-19 CA CA002323726A patent/CA2323726C/en not_active Expired - Lifetime
- 1999-03-19 EP EP04015041A patent/EP1555317B1/en not_active Revoked
- 1999-03-19 PL PL99343064A patent/PL343064A1/xx not_active IP Right Cessation
- 1999-03-19 EP EP07008204.5A patent/EP1857549B1/en not_active Expired - Lifetime
- 1999-03-19 WO PCT/AU1999/000195 patent/WO1999049029A1/en not_active Ceased
- 1999-03-19 EP EP99910039A patent/EP1071762A4/en not_active Ceased
- 1999-03-19 BR BRPI9908967A patent/BRPI9908967B1/pt active IP Right Grant
- 1999-03-19 NZ NZ506648A patent/NZ506648A/en not_active IP Right Cessation
- 1999-03-19 SG SG200205122A patent/SG115493A1/en unknown
- 1999-03-19 CA CA002513336A patent/CA2513336A1/en not_active Abandoned
- 1999-03-19 CN CNA2005100833251A patent/CN1796556A/zh active Pending
- 1999-03-19 CN CN99804255A patent/CN1294631A/zh active Pending
- 1999-03-19 AU AU29163/99A patent/AU743316C/en not_active Revoked
- 1999-03-19 EP EP05013010A patent/EP1624060B1/en not_active Revoked
- 1999-03-19 NZ NZ547283A patent/NZ547283A/en not_active IP Right Cessation
- 1999-03-19 AT AT04015041T patent/ATE526405T1/de not_active IP Right Cessation
- 1999-03-19 CZ CZ20003346A patent/CZ295108B6/cs not_active IP Right Cessation
- 1999-03-19 DK DK05013010.3T patent/DK1624060T3/da active
-
2000
- 2000-08-30 ZA ZA200004507A patent/ZA200004507B/xx unknown
-
2001
- 2001-11-30 US US09/997,905 patent/US20030074684A1/en not_active Abandoned
-
2002
- 2002-04-24 AU AU35647/02A patent/AU3564702A/en not_active Abandoned
-
2003
- 2003-08-22 US US10/646,070 patent/US7754697B2/en not_active Expired - Fee Related
-
2004
- 2004-04-08 US US10/821,710 patent/US20040237145A1/en not_active Abandoned
-
2005
- 2005-06-17 AU AU2005202658A patent/AU2005202658B2/en not_active Expired
- 2005-08-02 JP JP2005223953A patent/JP4187737B2/ja not_active Expired - Lifetime
- 2005-09-02 US US11/218,999 patent/US8168774B2/en not_active Expired - Fee Related
- 2005-09-09 AU AU2005209648A patent/AU2005209648B2/en not_active Expired
- 2005-09-15 AU AU2005211538A patent/AU2005211538C1/en not_active Expired
-
2007
- 2007-11-21 JP JP2007302237A patent/JP4460600B2/ja not_active Expired - Lifetime
-
2008
- 2008-11-21 AU AU2008249157A patent/AU2008249157B2/en not_active Ceased
-
2009
- 2009-07-08 JP JP2009161847A patent/JP4981103B2/ja not_active Expired - Lifetime
-
2012
- 2012-04-27 US US13/458,704 patent/US20120277285A1/en not_active Abandoned
-
2013
- 2013-12-20 US US14/137,737 patent/US9963698B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4187413B2 (ja) | 遺伝子発現の制御 | |
| MXPA00008631A (en) | Control of gene expression |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20040712 |
|
| RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20040712 |
|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20040728 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20040712 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20040728 |
|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20040826 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20040826 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20060919 |
|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20061207 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20061219 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20061226 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20061207 |
|
| A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20070319 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20070723 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20071121 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20071218 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20071221 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20071218 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20080129 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20080811 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20080909 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110919 Year of fee payment: 3 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120919 Year of fee payment: 4 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130919 Year of fee payment: 5 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| EXPY | Cancellation because of completion of term |